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DESIGN OF PEPTIDE-BASED PRODRUG CHEMISTRY AND ITS APPLICATION 
TO GLUCAGON-LIKE PEPTIDE I 
   
ABSTRACT – Peptide-based drugs are highly effective medicines with relatively short 
duration of action and of variable therapeutic index. Glucagon-like peptide 1 is a 
hormone that offers promise in the treatment of Type II diabetes. However, the biggest 
problem in the therapeutic use of GLP-1 is its extremely short half-life in plasma (~2 
min). A prodrug of GLP-1 should extend and improve the pharmacodynamics of this 
peptide hormone. We have designed prodrugs that slowly convert to the parent drug at 
physiological conditions of 37C and pH 7.2 driven by their inherent chemical instability 
without the need of any enzymatic cleavage. We observed that amide prodrugs could not 
convert to the active peptides under physiological conditions. Consequently, we decided 
to synthesize peptide drugs which had a hydroxy-terminal extension instead of a N-
terminal amine. Ester prodrugs were prepared using these hydroxy-peptides as the 
scaffold. We explored the diketopiperazine and diketomorpholine (DKP and DMP) 
strategy for the chemical flexibility that it offers to develop prodrugs with variable time 
actions. The esters proved to be more labile than the corresponding amides and the 
dynamic range in rate of cleavage ranged from an hour to almost half a week. We found 
that the rate of cleavage depends on the structure and stereochemistry of the dipeptide 
pro-moiety and also on the strength of the nucleophile. The careful selection of 
appropriate functionality that balances chemical, biological and immunological features 
under physiological conditions has also been reported.  
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Design of Peptide-based Prodrug Chemistry and its Application to 
Glucagon-Like Peptide I  
A) Introduction 
I) Diabetes: 
Diabetes is an ancient disease that continues to affect a diverse population in 
modern times. The first recorded cases of diabetes date to ancient times in Egypt and 
India (where it was called Madhumeha in ancient Ayurvedic medicine).1 The term 
"diabetes" was first coined by a Greek physician named Aretaeus of Capasdocia.1 
The prevalence of diabetes has grown steadily over the last thirty years, largely as 
a result of poor diet and a rapid rise in the prevalence of obesity.  Diabetes is a disease 
associated with sizable morbidity and excessive mortality. It imposes an immense 
financial burden on those afflicted with the disease and general societal health care costs.  
It is broadly accepted that there currently is a worldwide epidemic of Type 2 diabetes 
(often referred to as adult-onset diabetes).  Moreover, numerous clinical studies have 
shown that most cases could be prevented or managed by lifestyle modifications and 
proper medication.2  In certain demographic populations, like the Pima Indians of North 
America, as much as 30% of the adult population has been diagnosed with Type 2 
diabetes.  In the United States alone, 18 million people (6.3%) currently suffer from 
diabetes which in turn is a leading cause of blindness and heart attacks, as well as kidney 
and vascular disease 3,4. 
The primary physiological cause of diabetes is the defective utilization of glucose 
by insulin-responsive cells in the body. Consequently, blood glucose levels increase 
despite elevations in insulin concentrations and hyperglycemia eventually emerges. The 
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glucose accumulates in the blood instead of being absorbed and metabolized. Therefore, 
the cells do not generate enough energy to perform their normal activities while the 
persistently high blood glucose concentration is damaging to numerous tissues, especially 
the eyes, kidney and nerves.  
There are three different forms of diabetes that are distinguished by their 
etiological onset and progression. The physiological effects vary in severity and cause, 
but all induce similar types of damage to physical health. 
 
1) Type 1 diabetes: Type 1 diabetes is often referred to as juvenile diabetes 
because the majority of cases strike before adulthood.  This is a chronic disease of 
childhood and approximately 150,000 people under the age of 18 and more than a million 
people in total are afflicted by this disease in the United States alone. Its prevalence is 
rising at a rate of 3% a year.5 Over time, Type 1 diabetes can lead to serious medical 
complications such as cardiovascular diseases, diabetic retinopathy and diabetic 
neuropathy.6 Type 1 diabetes is most often the result of a humoral based auto-immune 
response against β cells of the islets of Langerhans which are located within the pancreas. 
These cells are responsible for producing the insulin required for normal metabolic 
homeostasis.  Such patients typically lose about 80-90% of their β cells7 and the 
remaining population is insufficient to meet the body’s normal insulin requirements. This 
leads to hyperglycemia or what is also known as “insulin-dependent diabetes”.  People 
diagnosed with Type 1 diabetes need to be treated with daily insulin injections.   
Type 1 diabetes also presents us with a challenging paradox. If the subjects could 
be identified before hyperglycemia occurs, the initiation of the autoimmune process 
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might be prevented, thus halting the development of diabetes. Unfortunately, a definitive 
diagnostic method to determine who will eventually develop Type 1 diabetes does not 
exist and attempts to develop such methods would require large numbers of test subjects. 
Without such a diagnostic, the development of an efficacious therapy is difficult since 
finding the subjects is very hard and the risk-benefit ratio of an experimental medicine in 
a subject prior to disease onset is unknown.6 
 
2)  Type 2 diabetes (non insulin-dependent): This is the more common form of 
diabetes. A healthy person’s body secretes enough insulin to maintain a steady blood 
glucose level. In Type 2 diabetes, the body does not produce enough insulin in a relative 
and often an absolute sense. Resistance to insulin action is a physiological hallmark 
feature of this disease. This resistance to insulin is often caused by obesity8. Although 
this is not a universal phenomenon, underweight patients are often found to have had 
impaired insulin secretion while the obese exhibit “insulin resistance”.9  
Approximately 90-95% patients that suffer from diabetes reportedly have Type 2 
diabetes10 which normally occurs after 40 years of age. Hence it is known as “adult-onset 
diabetes”. Due to changes in dietary habits and lack of exercise, it is no longer 
uncommon for Type 2 diabetes to occur in younger people, even adolescents.  This shows 
a strong correlation with the alarming rise in the prevalence of obesity and a sedentary 
lifestyle. 
3) Gestational diabetes: This occurs in pregnant women, hence the name.  If the 
blood glucose level is high in a woman during pregnancy but not at other times, then she 
is said to have gestational diabetes. The cause is currently unknown but seems similar to 
  4 
Type II diabetes where pregnancy imposes a level of insulin resistance. Approximately 
4% of pregnant women are purported to have this disease, and around 135,000 new cases 
are reported every year.11 Further observations show that approximately 50% of 
gestational diabetes reappears as Type II diabetes within two years of child bearing.11 
 
II) Insulin:  
In two landmark papers12, 13 in 1922, Fredrick Banting, Charles Best, James Collip 
and John Macleod reported the extraction of insulin from the pancreas of a dog. This 
extract was subsequently shown to lower the blood glucose level in surgically induced 
diabetic animal models.  The clear demonstration that diabetes is caused by the 
deficiency of insulin and could be reversed pharmacologically makes these two of the 
more important scientific papers of the 20th century. 
Insulin is a rather small protein, with a molecular weight of slightly less than 
6,000 Daltons. The primary amino acid sequencing was accomplished by Sanger in 
1959.14 It is composed of two peptide chains, designated as the A chain and B chain. The 
A chain has 21 amino acids while the B chain has 30. 
The chains are linked by two disulfide bonds (residues A7 to B7, and A20 to 
B19). In addition, there is a third intramolecular disulfide bond in the A chain (residues 
A6 to A11) (Fig 1). The complete conservation of these three disulfide bonds throughout 
the mammalian phylum underscores the critical importance of this bonding pattern. This 
also increases the structural complexity of the molecule and makes it more difficult to 
synthesize as compared to a single peptide chain. 
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Figure 1: Primary structure of Insulin 
 
There are three important pharmacodynamic characteristics of a drug: its onset 
(duration to biological action), its peak time (time at which the biological effect is 
strongest), and finally its duration (sustained time of biological activity). There are 
several unique forms of insulin designed to meet an individual patient's daily glucose 
demands (meal and fasting level). They are commonly classified into four broad 
categories by their duration of action: very fast, fast, slow, and very slow (Table I). 
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 *Since patients respond to insulin differently, the peak action and duration are given as 
ranges. 
 
Table 1: Pharmacodynamics of common insulin analogs 
 
The time action curves of some common insulin analogs are shown in Figure 2. 
Ultralente is a very slow acting insulin, hence it is usually used with Humalog® (very 
fast acting) or native regular insulin (fast acting)15 to more accurately mimic the normal 
daily physiological variation in insulin activity.  
 
 
Figure 2: Pharmacodynamics of common insulin analogs. 
 
Numerous combinations of these insulin analogs facilitate regulation of blood 
glucose in virtually all forms of diabetes. However, they all have several severe 
limitations. The most relevant is the finding that insulin overdose is the single most 
 Onset Peak Action* Duration* 
Humalog® 0.25 hr 0.5 – 1.5 hrs 3-5 hrs (very fast) 
Regular 0.5 hr 2-4 hrs 6-8 hrs (fast) 
NPH, Lente 1-3 hrs 6-12 hrs 18-24 hrs (slow) 
Ultralente 4-8 hrs 12-18 hrs 24-28hrs (very slow) 
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potent cause of life-threatening hypoglycaemia16. This has been confirmed by many 
clinical trials, most notably by the Diabetes Control and Complications Trial Research 
Group17. Studies performed in representative populations clearly demonstrate that weight 
gain is another problem associated with insulin therapy18. Such weight gain can 
paradoxically increase insulin resistance and thus the amount of insulin needed. Obesity 
also increases cardiovascular risks19.  
While insulin is a miraculous substance it is a challenging medicine. Its complex 
structure, especially its intra and intermolecular disulfide bonds makes it difficult to 
synthesize in an inexpensive manner and the molecule hard to formulate. Furthermore, 
the natural tendency of insulin to form insoluble multimeric complexes at high 
concentrations seriously complicates its commercial production. Additionally, the narrow 
therapeutic index and thermal instability of insulin over extended periods of time makes 
refrigeration a necessity. Lack of adequate refrigeration is a major issue in many parts of 
the world. 
What is most needed is a medicine that is capable of normalizing blood glucose 
without the risk of hypoglycemia. In this context, it is helpful to note that Glucagon-like 
peptide 1 (GLP-1) therapy has been shown to increase native insulin synthesis and 
secretion without inducing hypoglycemia20.  
 
III) Glucagon like peptide 1 (GLP 1):  
Glucagon-like peptide 1 is a hormone that offers the promise of revolutionizing 
the treatment of Type II diabetes. In a landmark paper published in 1985,21 two 
endogenous peptides were reported which had a high sequence homology to glucagon 
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and, like insulin, displayed high conservation across a range of different species. These 
two peptides were Glucagon-like peptide-1 (GLP-1) and Glucagon-like peptide-2 (GLP-
2) which were first identified in the course of cloning the gene for proglucagon. Upon 
testing, it was found that GLP-1 stimulated insulin release while GLP-2 did not21. Early 
clinical experiences suggested that GLP-1 has an attractive pharmacologic profile22. 
Throughout this thesis, GLP-1(7-37)-acid has been denoted simply as GLP with changes 
added to this nomenclature to signify related peptides. 
GLP is secreted from the gut in response to a meal23. It is an incretin hormone that 
has the potential to offer an ideal treatment for Type 2 diabetes24. GLP enhances the 
secretion of insulin25 only when the blood glucose level is high, eliminating the risk of 
hypoglycemia. It inhibits glucagon secretion therein maintaining an optimal ratio of 
insulin and glucagon26. GLP has further been shown to reduce food intake via its effects 
on gut motility (it inhibits the motility of the upper gut), leading to weight loss and 
decreased obesity26. Thus, GLP by virtue of its multiple biological actions has emerged 
as a valuable tool in the treatment of Type 2 diabetes, and related metabolic syndromes. 
There is another more physiological factor to rationalize GLP therapy. Type 2 
Diabetes is characterized by insufficient insulin secretion and declining β-cell function. 
This β-cell defect partly results from the progressive loss in β-cells function, as noted 
previously. GLP also has an apparent mitogenic effect on the β-cells of the pancreas27, 
and thus stimulates the in vivo biosynthesis of insulin (thus addressing the main defect of 
progressive decay in β-cell capacity) 26. Additionally, recent research demonstrates that 
almost two thirds of the insulin secreted in response to a meal is because of the action of 
insulinotropic actions of the incretin hormones, like GLP28. Indeed patients with Type 2 
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Diabetes have been long known to exhibit a variable loss in the incretin action of GLP29. 
In this way, GLP therapy addresses the physiological replacement for the loss in incretin 
action associated with Type 2 Diabetes. 
GLP stimulates the secretion of insulin by interacting with the GLP G-Protein 
Coupled Receptor (GPCR) expressed on the surface of β-cells of the pancreas. This 
receptor is coupled positively to the adenylyl cyclase system30. After ligand activation, 
the adenylyl cyclase is stimulated leading to an increase in cAMP concentration within 
the β-cells31. This in turn activates protein kinase A that leads to an avalanche of 
additional biochemical events32. GLP mediated receptor action via adenylate cyclase is 
the basis of our in-vitro bio-assay, and has proven useful in design of GLP analogs with 
therapeutic promise (see Experimental Design of Bioassays). It is to be noted that this 
insulinotropic effect of GLP is strictly glucose dependent33. 
Glucagon-like peptide 1 physiologically exists in two forms of comparable 
biopotency34. The first is the more abundant34 GLP(7-36) amide where the C terminus is 
an arginine amide (Figure 3A). The second form is the GLP(7-37) acid where the C 
terminus is a glycine (Figure 3B). The secondary structure of GLP-1 is shown in Figure 
3C. 
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    Figure 3A: Primary structure of GLP-1(7-36) amide and action of DPP IV 
 
           
      Figure 3B: Primary structure of GLP-1(7-37) acid and action of DPP IV. 
amide
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The 2D-NMR structure of GLP-1 has revealed that the first 7 residues show a random coil (pink) followed by a 
turn (yellow). This is followed by a helical region (red; residues 7-14), a linker region (yellow; residues 15-17) 
and another helical region (red; residues 18-25). The C-terminal region of GLP-1 is again a random coil. It is 
speculated that the N-terminal random coil region interacts with the receptor. The structure has been drawn using 
PDB Protein Workshop software. (Hui, H., et al. (2005) Diabetes/Metabolism Research and Reviews 21: 313-331)  
 
Figure 3C: 2D-NMR structure of GLP-1 
 
As illustrated in Figure 3C, it is thought that the N-terminal random coil region is 
important for receptor binding. Structure-activity relationship studies have shown that the 
N terminal histidine is especially important for the potency of GLP and the N-terminally 
extended forms severely diminish biological potency35.  We intend to take advantage of 
this finding to further advance out research hypothesis (see Hypothesis).  
The biggest problem in the therapeutic use of GLP is its extremely short half-life
 
in plasma (~2 min)36. The short half life results from the rapid degradation by Dipeptidyl 
Peptidase IV (DPP-IV) and the circulating levels further decrease due to high renal 
N-
terminus 
C-
terminus 
N-terminal random 
coil important for 
receptor binding 
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clearance37. As shown in Figure 3A and 3B, DPP-IV cleaves GLP between the alanine 
residue at position 8 and the glutamic acid residue at position 938. This cleavage not only 
inactivates the peptide but it also yields the residual GLP(9-36) amide; an antagonist at 
the GLP receptor39. Hence, to obtain reasonable glycemic control, the GLP should be 
administered continuously for a prolonged period36.  
Two other strategies have been formulated to use GLP signaling to treat Type 2 
diabetes:  use of a DPP-IV inhibitor40 or design of a longer-acting variant of GLP 
(pictorially represented in Figure 4).  
 
Figure 4: Pictorial explanation of GLP-1 therapy 
Longer lasting GLP1 
analogs / 
Prodrugs of 
GLP-1 
DPP-IV inactivates 
GLP-1 
        
GLP-1 
(very short 
half life) 
  
DPP-IV inhibitor drugs 
inhibit DPP-IV; thus  
increasing effective 
GLP-1 
concentration. 
Stimulates insulin Inhibits glucagon 
Lowers 
blood 
glucose 
level   
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The most obvious difference between these two therapies seems to be their effect 
on body weight. While native GLP and its analogs promote loss of weight, the DPP-IV 
inhibitors act by preventing gain of weight41. Additionally, several other issues regarding 
the feasibility of using DPP-IV inhibitors need to be addressed before effective 
therapeutic use42. Even after treatment with DPP-IV inhibitors it is not clear if there 
would be enough GLP to attain peak efficacy in the body. This is because the amount of 
endogenous GLP secreted is severely reduced in diabetes. The fact that DPP-IV non-
specifically acts on peptides other than GLP adds to its efficacy but is also a matter of 
concern. The larger issue pertains to the other useful functions of DPP-IV in different 
tissues, such that adverse effects of DPP-IV inhibitors are theoretically possible42.  
Our work concentrated on designing a prodrug for GLP i.e., a longer-acting 
variant of GLP. A few longer-acting analogs of GLP have been identified, two of which 
will be discussed below. The first peptide is Exendin-4 which is an agonist for GLP 
receptor43 and is found in the saliva of the Gila monster44 (Heloderma species native to 
several American States). Exendin-4 was discovered by John Eng, an endocrinologist at 
the Bronx Veteran’s Affairs Medical Center in New York. It is being marketed by 
Amylin Pharmaceuticals. Exendin-4 functions in a manner similar to that of native GLP 
with which it shares 53% amino acid homology. Several important functional residues 
like the N-terminal histidine are conserved. It is much more resistant to cleavage by DPP-
IV than GLP as a result of the glycine at the second residue instead of alanine. Thus, it is 
found that Exendin-4 has all the biological functions of GLP, but with a longer half life 
(60-90 minutes)45. While the t1/2 is much greater as compared to native GLP (t1/2 ~2min), 
an even longer-acting drug is highly desirable. Finally, since Exendin-4 is of non-human 
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origin, it has been reported to induce an immune response that compromises long-term 
clinical efficacy46.  
Another longer-acting GLP analog is called Liraglutide. In this peptide analog, 
there is an arginine in the 34th position instead of a lysine. Additionally, a glutamic acid 
residue is added to the lysine residue at position 2647 and the α-amine of this glutamate is 
acylated with a C16 fatty acid. Upon entering the bloodstream, the fatty acid non-
covalently binds to serum albumin (a protein facilitating plasma transport)48. The serum 
albumin distributes the drug throughout the body and also protects against cleavage47. As 
a result Liraglutide’s t1/2 is increased to about 10-14 hrs and the drug can be injected once 
a day. This drug is being developed by Novo Nordisk and has now entered Phase 3 trials. 
The N-terminal histidine of GLP (7th position as shown in Figure 3B) is important 
for pancreatic receptor activation of GLP and exendin-4.  Previous amino acid 
substitutions for this histidine with lysine and alanine have resulted in a large loss of 
bioactivity35. Hence it has been concluded that the imidazole ring of the histidine is 
necessary for the full potency of the molecule. GLP lowers blood glucose in diabetic 
patients, and might restore β cell sensitivity to exogenous insulin secretagogues. Studies 
so far have yielded evidence that GLP therapy is safe and effective for Type 2 diabetics49. 
We want to develop a longer-acting GLP prodrug, possibly with weekly or even monthly 
duration of in vivo biological action.   
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IV) Prodrug:  
A prodrug is the precursor of a drug. According to The International Union of 
Pure and Applied Chemistry (IUPAC), the term prodrug is defined as “any compound 
that undergoes biotransformation before exhibiting its pharmacological effects. Prodrugs 
can thus be viewed as drugs containing specialized non-toxic protective groups used in a 
transient manner to alter or to eliminate certain limiting properties in the parent 
molecule”50. The term “prodrug” was first introduced by Albert in 1950 to signify 
pharmacologically inactive chemical derivatives that undergo conversion endogenously 
to become an active pharmacological agent to increase their usefulness or decrease their 
toxicity51. In this regard, prodrugs can be used for various purposes. Most prodrugs are 
designed to facilitate high cellular absorption following administration52 (i.e. 
valaciclovir). Prodrugs must be soluble in an aqueous media to be absorbed properly. 
Insolubility of a drug can also cause significant pain at the site of injection. An example 
is clindamicyn where injections are painful, but its phosphate ester prodrug improves 
solubility and alleviates the pain53. The prodrug should be non-toxic, stable in storage and 
must be resistant to degradation in different body fluids until that point when it reaches 
its site of action. Finally after reaching the specific site of action, there should be a 
quantitative release of the drug53. 
The prodrug approach is commonly utilized with small molecules (less than 500 
Daltons)54 to enhance oral delivery. The main obstacle to using peptides as potential 
drugs is their short half life in the systemic circulation because of proteolytic hydrolysis 
and the rapid clearance by blood, liver and kidney55. A second limitation is their limited 
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oral absorption55. Due to these problems of short half life and poor oral bioavailability, 
alternative routes of delivery are being explored56. 
The prodrug that we envision has certain unique characteristics. Through 
structural refinement, we intend to appropriately extend the biological half life and 
broaden the therapeutic index of GLP. Our prodrug concept is not focused on oral 
bioavailability as with conventional small drug approaches, but upon extended biological 
half life. Consequently, many of the stringent necessities of conventional prodrugs are not 
relevant. Most prodrugs as described above are designed to facilitate transport across 
biological membranes. Our prodrug is used to delay the time of action by inhibiting 
recognition by the corresponding receptor. Receptor recognition is the primary means of 
degradation and thus termination of biological activity of our drug. We seek to convert 
our prodrugs to active peptides by controlling the chemical conversion to structures that 
can be recognized by the receptor. The speed of this chemical conversion will determine 
the time of onset and duration of in vivo biological action (Figure 5). 
The final element of this work is the application of selective pegylation57 to delay 
non-productive, premature, in-vivo clearance. Peptides are easily cleared because of their 
relatively small molecular size when compared to plasma proteins. Increasing the 
molecular weight of a peptide above 40kDa exceeds the renal threshold and significantly 
extends duration in the plasma. The judicious choice in the site of attachment of a 
polyethylene glycol polymer that is ten fold larger than insulin or GLP is a sizable 
challenge.  
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Figure 5A: General prodrug hypothesis 
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Figure 5B: Hypothesis (N-terminal amide and ester prodrug) 
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B) Hypothesis:  
We believe that by making a prodrug at the N-terminal end of GLP, it should be 
possible to extend and improve the pharmacodynamics of this peptide hormone (Figure 
5A and 5B). 
The ideal prodrug should be soluble in water at a pH of 7.2 and 37°C, and it 
should be stable in the powder form for long term storage. It should be immunologically 
silent and biologically inactive when injected in the body; and be quantitatively converted 
to the active drug within a defined period of time. Our greatest interest lies in prodrugs 
with a t1/2 of between 10-100 hrs (weekly, or even monthly duration) under physiological 
conditions (pH of 7.2 and 37°C). 
During the course of this research, we identified four GLP analogs that are 
physically and chemically stable, and whose conversion from prodrug to the active drug 
form under normal physiological conditions ranges within the optimal range. One of 
these peptides converts to GLP with a half life of 64 hrs. The in vivo extension in 
duration of action of this magnitude would constitute the longest acting peptide prodrug 
ever designed. These analogs possess a minimal alteration to the native amino acid 
sequence, and this should minimize potential adverse immunogenic affects. The 
bioactivities of these synthetic peptides have been determined using in vitro cellular 
assays. 
At the beginning of this research, many strategies were considered for 
constructing our prodrugs. It was contemplated that the protecting groups of the prodrug 
could be cleaved by enzymes as reported for nucleotide prodrugs58. However, we decided 
to design a prodrug that would slowly convert to the parent drug at physiological 
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conditions of 37оC and pH 7.2 driven by inherent chemical instability. The pH and 
temperature were relied upon for this conversion, as they are virtually invariant 
physiologically. We are seeking a prodrug that converts quantitatively to the drug under 
physiological conditions without the aid of any enzyme. The establishment of prodrug 
chemistry at the N-terminal end of GLP should be translatable for use with other peptides 
where this specific site is vital to bioactivity. 
We decided to synthesize a chemical derivative of GLP that would convert to 
GLP spontaneously as stated above. A few possible choices were contemplated before 
deciding that our primary target in prodrug chemistry would be diketopiperazine 
formation. The N-terminal histidine is important for the potency of our drug, and a 
reversibly modified histidine side chain was considered, as has been reported for 
Thyrotropin-Releasing Hormone (TRH)59. However, we dispensed with this approach 
since this prodrug chemistry is specific to the imidazole ring. This means that the prodrug 
chemistry requires the presence of a histidine, and possibly also at an N-terminal site.  
Thiol esters could also be synthesized by thioesterification60. However, a thiol 
ester is relatively unstable in physiology and thus would likely cleave too fast, thereby 
resulting in rapid clearance of the prodrug in its active form. Additionally, the use of 
thiol-based chemistry is fraught with other difficulties, such as instability of disulfide 
bonds. We decided to forgo this course of action. 
Our work therefore focused on making amide and ester prodrugs at the N-
terminus that upon cleavage of the suitable amide or ester bond generates the desired 
drug. Esters are normally more labile than amides; however they are easily hydrolyzed by 
the ubiquitous serum esterases53. Hence, amide bond based prodrugs were a much more 
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attractive design, although the risk of peptidase degradation may potentially complicate 
in vivo application. 
In considering amide prodrugs, it is reported that histidyl-proline amide cyclizes 
to a cyclo (His-Pro)61 at a pH of 7 and 37оC with a t1/2 of 140 minutes, with the release of 
NH3. The imidazole ring is purported to be playing a catalytic role at this pH. Hence, 
other dipeptides that did not have a histidine cleaved more slowly, and tripeptides did not 
cleave at all61. Thus, it seemed from this work that there might be a basic difference in 
the rate of diketopiperazine formation from the cleavage of a secondary amide (as in a 
tripeptide) as compared to a primary one (as in a dipeptide amide).  
In another paper62, the intramolecular aminolysis of Phe-Pro-p-nitroanilide (Phe-
Pro-pNA) to Phe-Pro-diketopiperazine (Phe-Pro-DKP) was studied as a function of pH. 
The pH-rate plot showed that the rate of the formation of the DKP was dependent on the 
degree of ionization of the N-terminal amino group, with the unprotonated free amine 
being more reactive than the protonated form. In their experiment, the authors used an 
activated, strongly electron withdrawing p-nitroanilide dipeptide instead of a natural 
tripeptide. This was because these p-nitroanilide dipeptides dissociate by DKP formation 
more rapidly than amino acid amides (i.e., natural dipeptides), thereby greatly facilitating 
their use in kinetic studies. The calculated t1/2 of conversion of a Gly-Pro-p-nitroanilide 
(Gly-Pro-pNA) dipeptide to Gly-Pro-diketopiperazine (Gly-Pro-DKP) under 
physiological conditions was about 120 hours. This is consistent with the previous 
assertion that there is a significant difference in the dissociation rate between a primary 
(around 140 minutes as in previous example61) and an activated secondary amide. It is 
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also important to note that in a natural tripeptide, the half life of the DKP formation 
would be further extended since there is no electronic assistance from the pNA. 
In both these papers61,62, it seems that the presence of proline in the C terminus of 
the dipeptide extension accentuates the formation rate of the DKP. This is likely due to 
contribution of the cis-proline conformer in the facilitation of the dipeptide's adoption of 
an optimal steric conformation for formation of DKP. The observations with 
modifications of an N-terminal residue upon the rate of DKP formation at pH 7.0 have 
been more varied. Reports suggest that it might depend on the pKa of the residue61, on its 
bulk63, or on the conformational stability of the resulting DKPs62. 
We also envisioned modification of a hydroxyl group at what otherwise would be 
the N terminus to prepare a depsi-peptide and thus make an ester prodrug. An ester can 
cleave hydrolytically64,65 or via the formation of five66,67 or six membered rings (like 
DKP). The ester prodrugs of Floxuridine (FUdR)65 convert by general ester hydrolysis 
i.e., a nucleophilic attack by water on the ester carbonyl. For the most part, the bulk of the 
pro-moiety influenced the hydrolysis of the FUdR prodrug (the Val ester prodrugs 
dissociated the slowest). In another paper, the authors studied the cyclization of the 
dipeptide esters in paracetamol to form a diketopiperazine68. They observed that they 
could obtain differential time action depending on the dipeptide structure. They also 
considered the possibility that in paracetamol, the drug release might have been via the 
general mechanism of ester hydrolysis and not the formation of a DKP ring. However, 
they eliminated it as in that case the nature of the dipeptide would have a lesser effect on 
reactivity. The proof of labile esters cleaving very fast under physiological conditions is 
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exemplified by the fast cleavage of the dipeptide esters in paracetamol where all the 
prodrugs had a t1/2 of less than 20 minutes68.  
In another investigational report, this time with cyclosporine-A prodrugs69,70 it has 
also been seen that through modulating the chemical nature of dipeptide esters it was 
possible to get conversion rates at physiological conditions ranging from minutes to 
several hours, but not longer. In these papers68,69, it seems that the presence of a 
minimally bulky glycine residue in the C terminus of the dipeptide extension accentuates 
the rate of formation of the DKP. This might be because of less bulk and the preferred 
conformational effect of glycine. However in the cyclosporine prodrug69, it seems 
unexpected that the presence of a proline in the C terminus of the DKP actually 
attenuates the rate of the conversion.  
In another investigation71, the C terminal amides of glycine were rapidly 
hydrolyzed at 25°C and a pH of 7 when the N-terminus was N-hydroxyethylated. The t1/2 
of bis-N-2-hydroxyethylglycinamide is three hours. In this case, the C terminal amide 
bond is activated by H bonding with the N-hydroxyethyl group. However, there was no 
practical way that one could modify the structure of the N-hydroxyethyl group as the 
precise Vander Waal radii were required to activate the amide group. 
Consequently, we explored the intramolecular cyclization reaction of dipeptide 
esters and amides to form diketopiperazine as an example of a chemoreversible prodrug 
(Figure 6). This chemistry is reasonably straightforward and allows at least four points 
(stereochemistry of R1 and R2, nature of the nucleophile and leaving group as shown in 
Figure 6A and 6B) where structure can be stereochemically controlled to refine the rate 
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of formation with release of the active peptide. Lastly, they can also be prepared from 
readily available alpha-amino acids using established chemistry72. 
As shown below (Figure 6A and 6B), prodrugs of varying half lives were 
designed by modifying R1 and R2. In the reaction below, there is an N-terminal histidine 
residue (native peptide), and an amide bond is being broken (Figure 6A). In the second 
equation, the ester bond of phenyllactic acid (hydroxyl phenylalanine) is being broken 
(Figure 6B). Though it might be beneficial to use the histidine in the 7th position of GLP, 
alternatives to the native N-terminal histidine were utilized for synthetic and analytical 
ease. Once the chemistry of a longer-acting prodrug is established, it is plausible to return 
to the histidine or for that matter any other suitably potent amino acid at the N-terminus. 
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Figure 6: Cleavage of amide (A) and ester prodrugs (B) 
 
Thus, we propose to make a prodrug that will slowly convert (t1/2 between 10-100 
hrs) to the parent drug at physiological conditions of 37оC and pH 7.2 so that they could 
be administered at a weekly or monthly frequency. As far as possible, a native sequence 
shall be used in the prodrug so as to minimize the chances of an immunological response. 
We rely on the pH and the temperature for this intramolecular conversion, as they are 
virtually invariant. It is of essence to note that this reaction should be concentration 
independent.  
 Four such peptides were identified with protracted half lives, with minimal 
potency as compared to the drug in the luciferase-based bioassay. These prodrugs 
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regained their potencies after incubation in PBS buffer at a pH of 7.2 and temperature of 
37°C. 
 Prodrugs of this thesis can be broadly classified into 4 different types of prodrugs: 
1. An amine nucleophile cleaving an amide bond (Class 1): This will dissociate with the 
formation of the corresponding 2,5-diketopiperazine. 
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2. A hydroxyl nucleophile cleaving an amide bond (Class 2): This will dissociate with the 
formation of the corresponding 2,5-diketomorpholine.  
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3. An amine nucleophile cleaving an ester bond (Class 3): This will dissociate with the 
formation of the corresponding 2,5-diketopiperazine. 
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4. A hydroxyl nucleophile cleaving an ester bond (Class 4): This will dissociate with the 
formation of the corresponding 2,5-diketomorpholine. 
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 The initial analysis was performed with the crude peptides. The rate of this 
reaction was not different from the pure peptides as this is an intramolecular cyclization. 
Additionally, it is also possible to observe our molecules of interest (both the prodrug and 
the drug) with a HPLC and MALDI analysis even in the midst of contaminating material. 
In most cases, an excellent mass balance for the disappearance of the prodrug and the 
appearance of the drug was observed. After we were satisfied that the crude prodrug had 
the required t1/2, the prodrug was purified and a standard luciferase-based bioassay was 
conducted to obtain relative potencies. 
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The experimental design of our bioassay was based on the general principles of 
“reporter gene technology”73 (Figure 7). In our case, the luciferase-based reporter gene 
assay for cAMP detection was used. The changes in the intracellular cAMP 
concentrations74 caused by the GLP receptor-mediated interactions are detected by the 
changes in the expression level of the luciferase gene. The transcription of this gene is 
regulated by the cAMP response-element binding protein (CREB) binding to cAMP 
response element (CRE). 
  This is an artificially created test system where the luciferase gene is downstream 
to the CRE which resembles nature’s response system all the way up to the point of gene 
expression where the luciferase gene is expressed. This modification is necessary as the 
concentration of activated luciferase is easier to measure than that of cAMP. 
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Figure 7: Pictorial Explanation of luciferase-based reporter gene assay 
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C) Experimental Procedure: Synthesis of GLP analogs 
 In this project, numerous GLP analogs were synthesized. The standard procedure 
is described briefly here, and the details are discussed later.  
PAM resin (PAM resin is OCH2-phenylacetamidomethyl–copolystyrene-1% 
divinylbenzene), (100-180 mesh, 1% DVB cross-linked polystyrene; loading of 0.7-
1.0mmol/g), Boc-protected and Fmoc protected amino acids were purchased from 
Midwest Biotech. Other reagents such as the α-hydroxy-acids (phenyllactic acid and 
glycolic acid) were purchased from Aldrich. The solid phase peptide syntheses using 
Boc-protected amino acids were performed on an Applied Biosystem 430A Peptide 
Synthesizer75. Fmoc protected amino acid synthesis was performed using the Applied 
Biosystems Model 433 Peptide Synthesizer. The manual synthesis of depsi-peptides was 
performed in sintered reaction vessels using analogous procedures75,76.   
 
I) Peptide synthesis (Boc amino acids/ HF cleavage):  
 The bulk of the synthesis was accomplished by using this method (Figure 8A). 
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Figure 8A: Peptide synthesis (Boc method) 
 
 Synthesis of these analogs was performed on the Applied Biosystem Model 430A 
Peptide Synthesizer. Synthetic peptides were constructed by sequential addition of amino 
acids, and activated esters of each amino acid were generated by the addition of 1.9mmol 
(3.8 ml of a 0.5M solution) of 3-(Diethoxy-phosphoryloxy)-3H-benzo[d][1,2,3] triazin-4-
one (DEPBT) in DMF to a cartridge containing 2mmol of Boc protected amino acid. The 
amino acids were dissolved by bubbling Nitrogen gas through the cartridge. 1 ml of N,N- 
Diisopropylethylamine was added to the cartridge to effect ester formation. This solution 
was transferred to the reaction vessel containing the 0.2 mmol of the C-terminal residue 
attached to the PAM resin, vortexed several times, and allowed to couple to the resin for 
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10 minutes. After washing to remove the unreacted reagents, the N-terminal Boc 
protecting group was removed by treatment with trifluoroacetic acid (TFA) for 5 minutes. 
The resin was washed with DMF and the cycle was repeated for the desired number of 
steps until the chain was assembled. The reaction vessel at the end of the synthesis 
(typically 30 amino acids) contained approximately 1.2-1.5g of protected peptidyl-PAM 
resin. The resin was washed numerous times with dimethylformamide (DMF), treated 
with trifluoroacetic acid to remove the last tBoc protecting group and finally washed 
several additional times with DMF, dichloromethane (DCM) and dried.  
 The peptidyl-resin was treated with anhydrous HF (procedure explained later in 
this section), and this typically yielded approximately 350 mg (~50% yield) of a crude 
deprotected-peptide. 
 
II) Peptide synthesis (Fmoc amino acids/ HF cleavage): 
 This synthesis scheme was performed manually with a few amino acids at 
selective sites. In this work, the Fmoc amino acids were used only to synthesize the 
internal serine prodrugs, as a part of a wider synthetic strategy. Here, it is to be noted that 
although FMOC chemistry has been used in the synthesis, the peptides have always been 
built on PAM resin that required treatment with HF to cleave the peptide from the solid 
support. The yield of these peptides is approximately as stated earlier for Boc/PAM 
synthesis. 
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   Figure 8B: Peptide synthesis (Fmoc method) 
 
 The synthesis was carried out as described in the previous section. At the end of 
the coupling step, the peptidyl-resin was treated with 20% piperidine to remove the N-
terminal Fmoc protecting group. It was washed repeatedly with DMF and this repetitive 
cycle was repeated for the desired number of coupling steps. The peptidyl-resin at the end 
of the entire synthesis was dried by using DCM, and the peptide was cleaved from the 
resin with anhydrous HF. 
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III) Depsi-peptide synthesis (Amino ester formation):  
 These syntheses76 were performed manually (Figure 9). In this case, the peptidyl-
resin had an α-hydroxyl-N terminal extension instead of a N-terminal amine and the 
acylation was done at the α hydroxyl group. This reaction takes a longer time than that of 
the amide bond formation, as the hydroxyl group is a weaker nucleophile as compared to 
the amine. The reaction time was typically 12 hours. 
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Figure 9: Depsi-peptide synthesis (Amino ester formation) 
 
 Initially, the activated esters of each amino acid were generated by the addition of 
1mmol (0.155 ml of Diisopropylcarbodiimide (DIC) to a cartridge containing a solution 
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of 2mmol of Boc protected amino acid residue in 2 ml DCM. This was cooled to 10˚C for 
10 minutes. 0.9 mmol (244 mg) of dimethylaminopyridine (DMAP) was added to the 
cartridge to accelerate ester formation. This mixture was transferred to the reaction vessel 
containing the peptidyl-resin upon which the peptide was synthesized. The reaction 
vessel was stirred for 12 hours.  
 The peptidyl-resin was dried using DCM and the synthesis of the desired peptide 
was continued. The peptidyl-resin at the end of the entire synthesis was dried by using 
DCM, and finally treated with anhydrous HF to generate the desired peptide. 
 
IV) N-terminal hydroxyl peptide synthesis (α hydroxyl- N terminal extension)74:  
 In this reaction, the free amine of the peptidyl-resin reacts with an α hydroxyl acid 
to form an α hydroxyl- N terminal extension (Figure 10). 
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Figure 10: α hydroxyl- N terminal extension 
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 In this regard, only two such α hydroxyl acids were used namely, glycolic acid 
(OH-glycine) and phenyllactic acid (OH-phenylalanine). These syntheses were also 
performed manually. The peptides were constructed by addition of the α hydroxyl acid, 
and activated esters of the α hydroxyl acid were generated by the addition of 0.9mmol of 
DEPBT (270 mg) to a cartridge containing a solution of 1mmol of Boc protected residue 
in 2 ml DMF. 0.5 ml of DIEA (N, N-Diisopropylethylamine) was added to the cartridge 
to accelerate ester formation. This mixture was transferred to the reaction vessel 
containing the peptidyl-resin upon which the peptide was synthesized. The reaction time 
was 6 hours.  
 The peptidyl-resin was dried using DCM and the synthesis of the desired peptide 
was continued. The peptidyl-resin at the end of the entire synthesis was dried by using 
DCM, and cleaved by anhydrous HF to generate the free peptide. 
 
V) HF treatment of the peptidyl-resin:  
 The peptidyl-resin (30mg to 200mg) was placed in the hydrogen fluoride (HF) 
reaction vessel for cleavage. 500µL of p-cresol was added to the vessel as a carbonium 
ion scavenger. The vessel was attached to the HF system and submerged in the 
methanol/dry ice mixture. The vessel was evacuated with a vacuum pump and 10ml of 
HF was distilled to the reaction vessel. This reaction mixture of the peptidyl-resin and the 
HF was stirred for one hour at 0°C, after which a vacuum was established and the HF 
was quickly evacuated (10-15 min). The vessel was removed carefully and filled with 
approximately 35 ml of ether to precipitate the peptide and to extract the p-cresol and 
small molecule organic protecting groups resulting from HF treatment. This mixture was 
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filtered utilizing a teflon filter and repeated twice to remove all excess cresol. This filtrate 
was discarded. The precipitated peptide dissolves in approximately 20ml of 10% acetic 
acid (aq). This filtrate, which contained the desired peptide, was collected and 
lyophilized. 
 
VI) Analysis using mass spectrometry: 
The mass spectra were obtained using a Sciex API-III electrospray quadrapole mass 
spectrometer with a standard ESI ion source. Ionization conditions that were used are as 
follows: ESI in the positive-ion mode; ion spray voltage, 3.9 kV; orifice potential, 60 V.  
The nebulizing and curtain gas used was nitrogen flow rate of .9L/min. Mass spectra was 
recorded from 600-1800 Thompsons at 0.5 Th per step and 2msec dwell time. The sample 
(about 1mg/mL) was dissolved in 50% aqueous acetonitrile with 1% acetic acid and 
introduced by an external syringe pump at the rate of 5 µL/min.  
 When the peptides were analyzed in PBS solution by ESI MS, they were first 
desalted using a ZipTip solid phase extraction tip containing 0.6 µL C4 resin, according 
to instructions provided by the manufacturer. 
(http://www.millipore.com/catalogue.nsf/docs/C5737) 
 
VII) High Pressure Liquid Chromatography (HPLC) analysis: 
 Preliminary analyses were performed with these crude peptides to get an 
approximation of their relative conversion rates in Phosphate Buffered Saline (PBS) 
buffer (pH, 7.2) using high performance liquid chromatography (HPLC) and MALDI 
analysis. The crude peptide samples were dissolved in the PBS buffer at a concentration 
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of 1mg/ml.  1ml of the resulting solution was stored in a 1.5ml HPLC vial which was 
then sealed and incubated at 37°C.  Aliquots of 100µl were drawn out at various time 
intervals, cooled to room temperature and analyzed by HPLC. 
 The HPLC analyses were performed using a Beckman System Gold 
Chromatography system using a UV detector at 214 nm. HPLC analyses were performed 
on a 150mm x 4.6mm C18 Vydac column. The flow rate was 1ml/min. Solvent A 
contained 0.1% TFA in distilled water, and solvent B contained 0.1% TFA in 90% 
CH3CN. A linear gradient was employed (40% to 70%B in 15 minutes). The data was 
collected and analyzed using Peak Simple Chromatography software. 
 The initial rates of hydrolysis were used to measure the rate constant for the 
dissociation of the respective prodrugs. The concentrations of the prodrug and the drug 
were estimated from their peak areas respectively. The first order dissociation rate 
constants of the prodrugs were determined by plotting the logarithm of the concentration 
of the prodrug at various time intervals. The slope of this plot gives the rate constant ‘k’. 
The half lives of the degradation of the various prodrugs were then calculated by using 
the formula t1/2 = .693/k. 
  
VIII) Preparative purification using HPLC: 
 After we were satisfied that the prodrug had an appropriate t1/2, the prodrug was 
purified. The purification was performed using HPLC analysis on a silica based 1 x 25cm 
Vydac C18 (5µ particle size, 300A° pore size) column. The instruments used were: 
Waters Associates model 600 pump, Injector model 717, and UV detector model 486. A 
wavelength of 214 nm was used for all samples. Solvent A contained 10% CH3CN /0.1% 
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TFA in distilled water, and solvent B contained 0.1% TFA in CH3CN. A linear gradient 
was employed (0 to 100%B in 2 hours).  The flow rate is 1.2ml/min and the fraction size 
was 6ml. From ~350 mgs of crude peptide, 80 mgs of the pure peptide (~23% yield) was 
typically obtained.  
  
IX) Bioassay Experimental Design: Luciferase-based reporter gene assay for cAMP 
detection 
The ability of each GLP analog or prodrug to induce cAMP was measured77 in a 
firefly luciferase-based reporter assay (Figure 7). The cAMP production that is induced is 
directly proportional to the GLP binding to its receptor. HEK293 cells co-transfected 
with the GLP receptor and luciferase gene linked to cAMP responsive element were 
employed for bioassay. 
The cells were serum-deprived by culturing 16 hours in Dulbecco Minimum 
Essential Medium (Invitrogen, Carlsbad, CA) supplemented with 0.25% Bovine Growth 
Serum (HyClone, Logan, UT) and then incubated with serial dilutions of either GLP 
analogs or prodrugs for 5 hours at 37oC, 5% CO2 in 96 well poly-D-Lysine-coated 
“Biocoat” plates (BD Biosciences, San Jose, CA). At the end of the incubation, 100 µL of 
LucLite luminescence substrate reagent (Perkin Elmer, Wellesley, MA) were added to 
each well. The plate was shaken briefly, incubated 10 min in the dark and light output 
was measured on MicroBeta-1450 liquid scintillation counter (Perkin-Elmer, Wellesley, 
MA). The effective 50% concentrations (EC50) were calculated by using Origin software 
(OriginLab, Northampton, MA). 
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D) Experimental Results and Discussion 
I) GLP-Oxyntomodulin 
 The GLP-oxyntomodulin chimeric peptide shown below was synthesized. The 
last eight amino acids were derived from oxyntomodulin and are shown in red. 
HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGKRNRNNIA 
 The rationale behind synthesizing this chimeric peptide is two fold. First, to 
demonstrate that a peptide of a mass of around 4300 Da could be synthesized.  Second, if 
this peptide is biologically potent, then a GLP analog with an extended C-terminus could 
be used for any future modification that might be required. This peptide has a mass of 
4322.5 Daltons (Figure 11A). In this way, the synthesis of GLP-oxyntomodulin was 
confirmed. The receptor binding activity of GLP-oxyntomodulin was determined in the 
GLP-receptor Luciferase assay (Figure 11B). 
 
Figure 11A: Mass spectra of purified GLP-oxyntomodulin chimeric peptide. 
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Figure 11B: Bioassay results of GLP-oxyntomodulin chimeric peptide 
 
 The GLP-oxyntomodulin was found to be at least as potent as the native GLP 
peptide in the luciferase assay. The GLP-oxyntomodulin also has a higher apparent 
maximal efficacy as compared to GLP (Figure 11B). This observation warrants additional 
study as the less potent oxyntomodulin also demonstrated super-efficacy. This signifies 
that the first portion of the project is successful and we focused on the central element of 
this study, specifically the N-terminal prodrug design. 
 
II) Adding dipeptides to the N terminus 
Dipeptides were covalently attached to the N-terminus of GLP (sequence in 
Figure 3B) to study differential tendencies for intramolecular cyclization and cleavage 
through diketopiperazine formation. This is represented schematically in Figure 12A. All 
class I prodrugs were synthesized by analogous procedures. 
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The biologically inactive dipeptide-extended GLP was converted to the active 
GLP upon cleavage of the amide bond along with the DKP (Figure 12B and Table 2).  In 
Figure 12C (Table 3 and 4), the same conversion is shown with the phenylalanine in the 
1st position of GLP. Prodrugs of varying half lives were envisioned by chemically 
modifying the R1 and R2 positions. This validates our reason for probing the DKP 
formation strategy. 
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Figure 12A: Schematic synthesis of Class I prodrugs 
  43 
pH=7.2
N
H
H
N
O
O
R1
R2
37oC
+ H2N-GLPO
NH
H
HN
HNH
N
O
H R2
GLP(8-37)
NH2
R1
6
5
 
       Figure 12B: Cleavage of amide bond to form DKP + H7,GLP(8-37) 
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Figure 12C: Cleavage of amide bond to form DKP + F7,GLP(8-37) 
 
The results of the cleavage in the prodrugs are shown in Table 2. The first peptide 
synthesized was named G5P6H7,GLP(8-37) where the R1 is the side chain for proline and 
R2 refers to the side chain for glycine (peptide 1 in Table 2). All peptides mentioned 
hereafter will have the same systematic nomenclature and the stereochemistry was 
assumed to be the l-isomer unless otherwise stated. The peptide was prepared 
synthetically by solid phase synthesis as described earlier. The synthesis was confirmed 
by MALDI-MS analysis (3509.5 Da) as shown in Figure 13. 
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Figure 13: Mass spectra of G5P6H7,GLP(8-37) 
 
To explore the possible formation of DKP, and simultaneous regeneration of the 
H7,GLP(8-37), the G5P6H7,GLP(8-37) was incubated in PBS buffer at 37˚C for 
approximately a week. Additionally, the peptide was heated at 100˚C to accelerate the 
amide bond cleavage. Analysis by reverse phase HPLC showed no apparent cleavage of 
the amide bond in this first set (Table 2). The structures of the peptides in Table 2 are 
illustrated in Appendix II. 
To investigate the propensity of various prodrugs to undergo DPK formation, all 
subsequent peptides were similarly synthesized and analyzed by MS and HPLC 
following treatment at 100˚C and 37˚C as described above. 
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Serial No Peptide (Xaa1Yaa2-
GLP1) 
Rate of cleavage at 
100˚C 
Rate of cleavage at  
37˚C 
1 GP No cleavage No cleavage 
2 PP No cleavage No cleavage 
3 γ Glu   No cleavage No cleavage 
4 E No cleavage No cleavage 
5 P No cleavage No cleavage 
6 H No cleavage No cleavage 
7 PH No cleavage No cleavage 
In 4, 5 and 6, there is just a single amino acid added to the N terminus of GLP-1. In 7, the dipeptide 
modification was made to sandwich the carbonyl bond of interest between two histidines. In all these cases 
there is histidine in the 1stposition (histidyl leaving group) of GLP-1. 
 
Table 2: Attempted cleavage of H7,GLP(8-37) prodrugs to form native GLP-1 
 
 
The dipeptide extension of peptides 1 and 2 in Table 2 were synthesized to 
facilitate DPK formation by sterically assisting in the cleavage of the amide bond. It was 
thought that the cis-orientation of proline would contribute in the facilitation of the 
dipeptide's adoption of an optimal steric conformation for the formation of DKP. 
However, the amide bond is quite robust and did not cleave. In peptides 3, 4, 5 and 6, an 
acid-base catalyzed general hydrolysis of the amide bond was attempted. Since, the 
leaving group will be the histidine at the N-terminus, it was purported that the imidazole 
ring might in some way assist in the cleavage by general acid-base catalysis. In 7, the 
carbonyl bond of interest is sandwiched between two histidines (amino acid Y and the 
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histidyl leaving group). This design was directed at a proton assisted cleavage of the 
amide bond via diketopiperazine formation. But even this prodrug did not cleave. 
At this point, it was speculated that perhaps the imidazole nucleus was playing an 
attenuating role in the cleavage of the amide bond. To test this possibility, a different 
leaving group was studied. F7,GLP(8-37) was synthesized and purified using the standard 
procedure described above. It was determined to be a full agonist with 10% the potency 
of native GLP. Dipeptides were added to this GLP analog to study the same type of 
reaction as described above (Table 3; reaction shown in Figure 12C). The structures of 
the peptides in Table 3 are drawn out in Appendix III. 
 
Serial No Peptide (Xaa1Yaa2-
F7a-GLP8-37) 
Rate of cleavage at 
100˚C 
Rate of cleavage at  
37˚C 
1 GP No cleavage No cleavage 
2 GSarb No cleavage No cleavage 
‘a’: In all these cases there is phenylalanine in the 1st  position (phenylalanyl leaving group) of GLP. 
‘b’: Sar represents sarcosine 
 
Table 3: Attempted cleavage of dipeptide extended F7,GLP(8-37) 
 
The dipeptide extension of peptides 1 and 2 (Table 3) were designed to sterically 
assist in the cleavage of the amide bond. In peptide 2, sarcosine was used69, as it has been 
previously reported to enhance the rate of cleavage. However, the amide bond remained 
resistant to cleavage. 
 A minor difficulty was encountered at this point. It seemed that the F7,GLP(8-37) 
analogs were not very soluble in PBS at 37˚C. Hence, we focused on a modified GLP 
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analog; GLP(7-36)-CEX amide where the C terminus is a serine amide. The CEX 
sequence is the C-terminal nine amino acids of exendin-4. The last nine amino acids were 
derived from exendin-4 and are shown in red.  
H7AEGTFTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS-
amide  
This peptide been observed in our laboratory to be ten times more potent in vitro 
than the native GLP sequence, and its analogs are appreciably soluble in PBS. 
Throughout this thesis, GLP(7-36)-CEX amide has been denoted simply as GLP(7-36)-
CEX with changes added to this nomenclature to signify related peptides.  
 
III) Adding dipeptides to the N terminus of F7,GLP(8-36)-CEX 
G5G6F7,GLP(8-36)-CEX (class 1) and OH-G5G6F7,GLP(8-36)-CEX (class 2) were 
synthesized to determine if either of the nucleophiles (amine or hydroxyl) could cleave 
the amide bond by 2,5-diketopiperazine or 2,5-diketomorpholine formation respectively 
and thus regenerate the F7,GLP(8-36)-CEX. The two compounds are shown below 
(Figure 14A). The schematic synthesis of the class 2 prodrug is represented in Figure 
14B.  All subsequent Class II prodrugs were synthesized by analogous procedures. 
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Figure 14A: Dipeptide extended F7,GLP(8-36)-CEX 
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  Figure 14B: Schematic synthesis of Class II prodrugs 
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The analyses of the two peptides after incubation in PBS (Figure 14A and Table 
4) showed that neither the amine, nor the hydroxyl nucleophile could cleave the amide 
bond. The structures of the peptides in Table 4 are also illustrated in Appendix IV (along 
with the relevant stereochemistry). 
 
Serial No Peptide (Xaa1Yaa2-
F7a-GLP-CEX) 
Rate of cleavage at 
100˚C 
Rate of cleavage at  
37˚C 
1 GG (class 1) No cleavage No cleavage 
2 HO-GG (class 2) No cleavage No cleavage 
‘a’: In all these cases there is phenylalanine in the 1st  position (phenylalanyl leaving group) of GLP. 
 
Table 4: Attempted cleavage of dipeptides attached to the N terminus of F7,GLP(8-
36)-CEX 
 
Representative HPLC analyses of G5G6F7,GLP(8-36)-CEX dissolved in PBS 
before and after treatment at 100˚C for two hours is shown in Figure 15. This analysis 
was done with the crude peptide. The amide bond did not cleave and the DKP was not 
generated. This was reflected by the absence of a shift of the HPLC peak in the elution 
profile of the prodrug to that of the dipeptide-shortened peptide drug F7,GLP(8-36)-CEX 
(not shown here) even when heated at 100˚C.  
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1) G5G6F7,GLP(8-36)-CEX  
        in PBS at 37˚C (0 min) 
                                                                                    
                                                 
 
                                                                                                                                           
2) G5G6F7,GLP(8-36)-CEX 
       in PBS at 100˚C (120 min) 
 
Figure 15: HPLC analysis of G5G6F7,GLP(8-36)-CEX 
 
In Table 5, the analyses of two peptides with a glycine at the N-terminal position 
are shown. These peptides were tested to check the effect of the less bulky glycyl leaving 
group, as opposed to the previously studied phenylalanine in Table 4. The structures of 
the peptides in Table 4 are displayed in Appendix V. 
 
Serial No Peptide 
(Xaa1Yaa2-G7a-
GLP-CEX) 
Rate of cleavage at 
100˚C 
Rate of cleavage at  
37˚C 
3 GG (class 1) No cleavage No cleavage 
4 HO-GG (class 2) No cleavage No cleavage 
‘a’: In all these cases there is glycine in the 1st  position (glycyl leaving group) of GLP. 
 
Table 5: Attempted cleavage of dipeptides added to the N terminus of  
G7,GLP(8-36)CEX 
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Based on the results shown in Table 5, it was concluded that the amide bond is 
very difficult to cleave under physiological conditions either by 2,5-diketopiperazine 
(DKP) or 2,5-diketomorpholine (DMP) formation. This is independent of the 
nucleophiles and leaving groups tested, even under elevated temperature. The focus of 
this study then moved to esters which were anticipated to be easier to cleave as compared 
to the amides.  
 
IV) Depsi-peptides and Esters 
Depsi-peptides were synthesized through addition of dipeptides to the hydroxyl 
group at the N terminus of another peptide via an ester linkage (Figure 9). The coupling 
procedures are described in the experimental section and they proved highly effective. As 
before, dipeptides of differential tendency for intramolecular cyclization 
(diketopiperazine formation) and release of the parent drug (N-terminal hydroxyl peptide) 
were studied. While adding the dipeptide, both Class 3 (an amine nucleophile cleaving an 
ester bond) and Class 4 (a hydroxyl nucleophile cleaving an ester bond – Figure 10) 
compounds were prepared and studied.  
The initial work began with imidazole-lactic acid (OH-His) as the terminal amino 
acid and subsequent leaving group. The HO-His7,GLP(8-37) was synthesized. It was a 
full agonist with 25% the potency of native GLP-1. There were several attempts to add a 
dipeptide to the α hydroxyl group of HO-His7,GLP(8-37) and test for the cleavage of the 
new ester bond. However, there was a problem in selectively acylating the α-hydroxyl 
group of this peptide. As “protected” imidazole lactic acid was not commercially 
available, we decided initially to work with the compound where the imidazole group 
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was unprotected. As a result, the “unprotected imidazole” was inadvertently acylated 
along with the hydroxyl group. A synthetic scheme for the preparation of HO-
His7,GLP(8-37), its subsequent acylation and the formation of multiple side-products is 
depicted in Appendix VIII.  
Consequently, Phenyllactic acid (OH-phenylalanine) was chosen in this initial test 
as it was readily available, and the return to a protected HO-His would be conducted if 
the work with HO-Phe proved successful.   
 
V) Adding dipeptides to the OH terminus of HO-F7,GLP(8-36)-CEX 
The HO-F7,GLP(8-36)-CEX peptide was synthesized from the GLP(8-36)-CEX 
PAM resin (the synthetic scheme is represented in Figure 16A) and served as the parent 
drug for these experiments. This peptide has an EC50 value of 0.008nM (gold color in 
Figure 16B) while native GLP has an EC50 value of 0.011nM. Therefore, the HO-
F7,GLP(8-36)-CEX was found to be at least as potent as the native GLP-1. This is a most 
important and a somewhat unexpected observation that the histidine can be substituted by 
phenyllactic acid. This warranted additional validation. Subsequent experiments yielded 
identical results. The possibility exists that this result is a function of the CEX extension 
in the HO-F7,GLP(8-36)-CEX. In this regard, it has been reported that the C-terminal 
region of exendin-4 increases its affinity to the GLP receptor78.  
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Figure 16A: Schematic synthesis of HO-F7,GLP(8-36)-CEX 
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Figure 16B: Bioassay results of HO-F7,GLP(8-36)-CEX 
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The α hydroxyl group of HO-F7,GLP(8-36)-CEX was acylated and both Class 3 
(an amine nucleophile cleaving an ester bond; Figure 17A) and Class 4 (a hydroxyl 
nucleophile cleaving an ester bond; Figure 17B) compounds were prepared and studied. 
Along with the 2,5-diketopiperazine (amine nucleophile) or 2,5-diketomorpholine 
(hydroxyl nucleophile), the biologically active HO-F7,GLP(8-36)-CEX is released as 
shown in Figure 17C.  
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Figure 17A: Schematic synthesis of Class III prodrugs 
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Figure 17B: Schematic synthesis of Class IV prodrugs 
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A) Amine cleaving ester (Class 3): 
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B) Hydroxyl cleaving ester (Class 4):                                                                                                              
 
pH=7.2
O
H
N
O
O
R1
R2
37oC
HO-F7-GLP(8-36) CEX
O
NH
O
O
OH
H
CH2Ph
GLP(8-36)CEX
H R2
H
R1
6
5
 
  
Figure 17C: Cleavage of A) Class III and B) Class IV prodrugs 
 
To explore the possible formation of 2,5-diketopiperazine (DKP) or 2,5-
diketomorpholine (DMP) and the simultaneous generation of HO-F7,GLP(8-36)-CEX, 
the prodrug was incubated in PBS buffer at 37˚C for approximately a week. The peptide 
was also heated at 100˚C to determine the susceptibility to cleavage (Table 6). The 
structures of the peptides in Table 6 are illustrated in Appendix VI. 
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Serial No Peptide (Yaa1Xaa2-O-Phe7-GLP-8-36-
CEX)                                                                     
t1/2* of cleavage at  37˚C 
1 Gly-Gly (class 3) 0.87 hrs             
2 HO-Gly-Gly (class 4) 1.13 hrs                 
3 HO-Phe-Val (class 4) No cleavage           
4 HO-Phe-dVal (class 4) 50.58 hrs                 
5 HO-Phe-Ala (class 4) 2.83 hrs                    
6 HO-Phe-dAla (class 4) 2.41 hrs                      
7 HO-Phe-Gly (class 4) 2.46 hrs                      
8 HO-Phe-Phe (class 4) 33.31 hrs             
9 HO-Phe-dPhe (class 4) 7.65 hrs                 
10 Phe-Val (class 3) 64.0 hrs                     
* t1/2 is the time required for 50% release of the HO-Phe-GLP8-36-CEX  at 37°C in PBS (pH7.2). It is 
calculated by a standard first order reaction plot. All these esters, including #3 cleaved at 100°C. In all these 
cases, there is HO-Phe in the 1st  position (hydroxy phenylalanyl leaving group) of GLP. 
 
Table 6: Cleavage of dipeptide extended HO-F7,GLP(8 36)-CEX 
 
The first two peptides shown in Table 6 (Peptides 1 and 2) were analyzed to 
determine if either of the nucleophiles (amine or hydroxyl) could cleave the ester bond by 
DKP or DMP formation respectively. The results validated our expectation that the esters 
are more susceptible to cleavage than the amides. The relatively slower rate of cleavage 
of peptides 3, 4, 8, 9 and 10 seem to suggest that the bulk of the dipeptide extensions 
(Phe or Val) greatly affect the rate of dissociation of the prodrug. While there is virtually 
no difference between a methyl and a hydrogen side chain (5, 6 and 7), the presence of an 
isopropyl group (β branching) greatly attenuates the rate of ester cleavage as evidenced in 
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peptides 3, 4 and 10. Peptide 10 dissociates faster than peptide 3 as the amine is a 
stronger nucleophile as compared to the hydroxyl, a point corroborated by peptides 1 and 
2 as well. Finally, the large difference in the t1/2 between peptides 8 and 9 indicates that 
the side chain interactions in the dipeptide (R1 and R2 in Figure 17C) play an important 
role as well. This same effect is shown by peptides 3 and 4.  In both instances, the L,D-
dipeptide diastereoisomer cleaves faster than the corresponding L,L- diastereoisomer.  
Peptides 3 to 9 are represented as shown in Figure 18A. The observed half life of 
the prodrug increases as the substituent X gets bulkier (3, 4, 8, 9 and 10 in Table-6). This 
is probably because the transition state (TS) is more sterically hindered as the size of X 
increases. Consequently, the energy of activation increases thereby increasing the half 
life of the prodrug (Refer to Figure 22).   
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  1      2 
1: L,L-dipeptide extension                               2: L,D-dipeptide extension 
 
Figure 18A: HO-F5X6-O-F7,GLP(8-36)-CEX structures 
 
This is especially exemplified for the two pairs of stereoisomers (3 and 4; 8 and 
9). Here, by changing the stereochemistry of a single amino acid in the C-terminus of the 
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dipeptide extension, a huge difference in rate was observed. The steric hindrance of the 
corresponding transition states is far greater in a L,L-dipeptide diastereoisomer (Analog 1 
in Figure 18A) as compared to a L,D- diastereoisomer (Analog 2 in Figure 18A). Hence, 
3 has a greater t1/2 as compared to 4, and 9 has a t1/2 greater than 10. 
Compound 10 is F5V6-O-F7,GLP(8-36)-CEX (Figure 18B). This has a t1/2 of 64 
hrs and represents the longest duration peptidic prodrug to cleavage under physiological 
conditions, reported to date. The transition state in this case is sizably hindered because 
of the steric interaction between the phenylalanyl and the valyl side chain. 
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Figure 18B:  F5V6-O-F7,GLP(8-36)-CEX (t1/2=64 hrs) 
 
The experimental data supporting the cleavage of compound 10 (Figure 18B) 
(4264 Da) to form the parent drug HO-F7,GLP(8-36)-CEX (4019 Da) is shown in Figure 
19. Since the reaction studied is an intramolecular cyclization, it is assumed that the 
presence of other impurities in the sample does not affect the rate of internal dissociation. 
In addition, both our molecules of interest (the prodrug and the drug) have been followed 
with a MALDI analysis even in the midst of contaminating material. 
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Phe-Val-O-F7-GLP8-36 CEX (4264Da) in PBS at 37˚C at 0 min. 2) Phe-Val-O-F7-GLP8-36 CEX (4264Da) cleaving to 
the parent HO-F7-GLP 8-36 CEX (4019 Da) after incubation in PBS at 37˚C for 64 hours.  
 
Figure 19: Cleavage of F5V6-O-F7,GLP(8-36)-CEX to form 
HO-F7,GLP(8-36)-CEX 
 
A second set of analogous depsipeptides were also studied to further examine the 
effects of the dipeptide extension structure upon the rate of cleavage (Table 7). Their 
4264 Da 
4019.122 Da 
4263.745 Da 
1 
2 
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synthesis follows the same pattern as outlined in Figure 17A and 17B. The major 
difference is that in this case, the R2 or Y site is a less hindered hydrogen (glycyl residue) 
instead of a bulky phenylalanyl as used previously (refer to Figure 17C and Figure 20). In 
this case a glycolic acid (OH-glycine) or a glycine were used at the terminal end of the 
peptidic prodrug. The structures of the peptides in Table 7 are illustrated in Appendix 
VII. 
 
Serial No Peptide (Yaa1Xaa2-O-Phe7-GLP-8-36-
CEX)                                                                     
t1/2 of cleavage at  
37˚C 
1 Gly-Gly (class 3) 0.87 hr               
2 HO-Gly-Gly (class 4) 1.13 hrs               
3 HO-Gly-Val (class 4) 4.70 hrs               
4 HO-Gly-dVal (class 4) 5.13 hrs                
5 HO-Gly -1AIB (class 4) 0.75 hrs        
6 HO- Gly -2PhG (class 4) 0.49 hrs             
7 HO- Gly -3tBut (class 4) Did not cleave 
8 HO- Gly-Phe (class 4) 0.70 hrs               
9 HO-Gly-dPhe (class 4) 0.93 hrs     
10 Gly -Val (class 3) 20.38 hrs     
t1/2 is the time required for 50% release of the HO-Phe-GLP8-36-CEX at 37°C in PBS (pH7.2). It is 
calculated by a standard first order reaction plot. All these esters cleaved at 100°C. In all these cases, there is 
OH-Phe in the 1st  position (hydroxy phenylalanyl leaving group) of GLP. 
1AIB: α-aminoisobutyric acid; 2PhG: phenylglycine; 3tBut: tertiary butyl;  
 
Table 7: Cleavage of ester bond in HO-G5X6-O-F7,GLP(8-36)CEX 
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The analysis was completed in the same manner as explained previously. The first 
two peptides shown in Table 6 (Peptides 1 and 2) were analyzed to determine if either of 
the nucleophiles (amine or hydroxyl) could cleave the ester bond by 2,5-diketopiperazine 
or 2,5-diketomorpholine formation respectively. These two peptides had been analyzed in 
Table 6 and were tested again to serve as a control. As expected, both of the nucleophiles 
studied could cleave the ester bond. This set of compounds (Analogs 2 to 9 in Table 7) 
can be represented as shown in Figure 20. 
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Figure 20: HO-G5X6-O-F7,GLP(8-36)CEX structures 
 
These peptides are expected to cleave faster than in the previous case, as the steric 
bulk is removed (glycyl group in Figure 20 as compared to the phenylalanyl in Figure 
18A). As the size of X becomes structurally bulkier, the transition state gets increasingly 
crowded. Consequently, the energy of activation increases thereby increasing the half life 
of the prodrug (Refer to Figure 22). This is what is seen in peptide 10 where X is an 
isopropyl (valine) group. When X is a tertiary butyl group (peptide 7), the compound 
does not cleave at all in PBS buffer (pH, 7.2) at 37°C (Figure 21). In Table 7, the pairs of 
stereoisomers (Analogs 3 and 4; 8 and 9) dissociate at nearly the same rate. This is 
probably because the stereoisomers do not show a large difference in energy (purportedly 
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because of the non-chiral nature of glycine). Hence, in this case, both the glycyl,L-
dipeptide extension and the glycyl,D-dipeptide extension have a comparable energetic 
transition state.   
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 1      2 
1: G5V6-O-F7,GLP(8-36)CEX           2: HO-G5tBuG6-O-F7,GLP(8-36)CEX 
(t1/2=18 hrs)                            (did not cleave at all) 
 
Figure 21: Dipeptide extended HO-F7,GLP(8-36)-CEX 
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Figure 22: Transition State diagram 
 
The observation that peptide 3 dissociates faster than peptide 10 seems to suggest 
that the hydroxyl is a stronger nucleophile as compared to the amine at a pH of 7.2 and 
37°C. One possible explanation for this anomaly might be that the pKa of the N-terminal 
amine (which is normally approximately 7) is slightly increased in peptide 10. As a 
result, at a pH of 7.2, this amine nucleophile would be disproportionately protonated and 
thus account for the slower rate of dissociation of the prodrug. This is just one possibility 
to explain the observed results but additional study is needed to determine the exact basis 
of this observation.  
Thus, our results suggest that the structural nature of the side chain (especially β 
branching as evidenced in dipeptides containing valine and tert-butyl glycine); the 
stereochemistry and the pKa of the nucleophile serve an important role in determining the 
relative rate of cleavage. Several fast and slow acting ester prodrug candidates have been 
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identified which were tested for their potency. As described earlier in our hypothesis, a 
prodrug should have minimal potency as compared to the drug, and its potency should 
increase consistent with the speed of cleavage of the dipeptide extension. 
 
VI) Bioassays of selected longer-acting prodrug candidates 
Four of the longer duration prodrugs were chosen for further analysis in the 
biopotency tests. Luciferase-based bio-assays were performed after purifying all these 
peptides by HPLC and confirming their masses by MALDI-MS analysis. Percent potency 
was calculated for purposes of comparing the mean EC50 of the parent with that of the 
respective prodrug. The results are tabulated in Table 8 and then pictorially represented in 
Figure 24A and B. The peptides tested in Table 8 are represented below in Figure 23. The 
syntheses of these prodrugs are schematically shown in Appendix I. 
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Figure 23: Structures of the peptides represented in Figure 24 and Table 8 
HO-F7,GLP(8-36)-CEX 
(red) 
HO-F5dV6-O-F7,GLP(8-36)-
CEX (t1/2 = 50.5 hr) (navy blue) 
F5V6-O-F7,GLP(8-36)-CEX (t1/2 
= 64 hrs) (sky blue) 
HO-F5F6-O-F7,GLP(8-36)-CEX 
CEX (t1/2 = 33.3 hr) (pink) 
G5V6-O-F7,GLP(8-36)CEX (t1/2 
= 20.3 hr) (yellow) 
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Serial 
No 
(Color) 
Peptide (t1/2): 
(Yaa1Xaa2-O-Phe-GLP-8-
36-CEX)                                                                     
EC50 ± Std. 
deviation (nM) 
% potency with 
respect to parent 
1 (red) HO-F7-GLP8-36 CEX (parent 
drug candidate) 
0.028 ± 0.006 100% (parent drug) 
2 (navy 
blue) 
HO-Phe-dVal (t1/2 = 50.5 hrs) 0.40 ± 0.06 7% 
3 (sky 
blue) 
Phe-Val (t1/2 = 64.0 hrs) 2.070 ± 0.41 1.3% 
4 (pink) HO-Phe- Phe (t1/2 = 33.3 hrs) 0.771 ± 0.249 3.6% 
5 
(yellow) 
Gly-Val (t1/2 = 20.3 hrs) 0.230 ± 0.10 12% 
The color code refers to the respective peptides represented in the Figure 22. Percent potency 
calculations were done comparing the mean EC50 of the parent with that of the prodrug.  
 
Table 8: Bioassay of select longer-acting ester prodrugs 
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GLP-1 Receptor-Transfected Cells
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Figure 24A: Bioassay results of select longer-acting prodrugs 
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Figure 24B: Histogram showing the potency of various prodrugs 
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These observations clearly show that addition of an ester linked dipeptide 
sequence to the terminal-hydroxyl group of the parent drug drastically reduces the 
potency of the drug. Two peptides were further analyzed to demonstrate that the prodrugs 
revert towards the potency of the parent drug following incubation for 24 hours, in PBS 
(pH, 7.2). The peptides chosen were analogs 4 and 5, based upon their physiologically 
relevant t1/2 values being closest to 24 hours (Table 9). 
These experiments were performed using HPLC purified samples with the 
luciferase-based assay. Percent potency calculations were done comparing the mean EC50 
of the parent with that of the prodrug. The results are tabulated in Table 9 and then 
pictorially represented in Figure 25. 
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Serial No 
/ (Color) 
Peptide (t1/2): 
(Yaa1Xaa2-O-Phe-GLP-8-
36-CEX)                                                                     
EC50 ± Std. 
deviation (nM) 
% potency with 
respect to parent 
Black HO-F7-GLP8-36-CEX 
(parent drug candidate) 
0.023 ± 0.010 100% (parent drug) 
5(168 hrs) 
(red)* 
Gly-Val (t1/2 = 20.3 hrs) 
incubated for 168 hrs. 
0.024 ± 0.012 95.8 % 
4(0 hrs) (navy 
blue)  
HO-Phe- Phe (t1/2 = 33.3 hrs) 
before incubation. 
0.612 ± 0.270 3.7 % 
4(24 hrs)  
(sky blue) 
HO-Phe- Phe (t1/2 = 33.3 hrs) 
incubated for 24 hrs. 
0.134 ± 0.050 17.2 % 
5(0 hrs)  
(pink) 
Gly-Val (t1/2 = 20.3 hrs) 
before incubation. 
0.211 ± 0.072 10.9 % 
5(24 hrs)  
(gold) 
Gly-Val (t1/2 = 20.3 hrs) 
incubated for 24 hrs. 
0.05 ± 0.020 46 % 
*- Peptide 5 after incubation in PBS for a week (potency almost completely restored). 
() 
– Time inside parenthesis refers to the time of incubation of the respective peptide 
The color codes refer to the colors with which the respective peptides are represented in the Figure 23.  
 
Table 9: Bioassay results that show the conversion of prodrugs to drugs 
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GLP-1 Receptor-Transfected Cells
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Figure 25: Bioassay results that show the reversal of prodrugs to drugs 
 
Prodrug 5 has its potency converted close to that of the parent drug after 
incubation for a week (shown in red). Both prodrugs display a higher potency after being 
incubated in PBS for 24 hours due to gradual conversion to the parent drug. Thus the 
definition of a prodrug has been substantiated by our data. Prodrug 4 exhibited a 17.2% 
conversion (sky blue) after being incubated in PBS for 24 hrs. This is less than predicted 
by the calculated half-life of this prodrug (Table 8). The reason for this apparent disparity 
in the quantitative conversion rate of prodrug 4 has not yet been determined, though 
expected statistical variation in our bio-assay results and the instability of the parent drug 
in the bio-assay might account for this discrepancy. Future study of prodrug 4 will have 
multiple time points to help us understand this disparity. 
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VII) Ester prodrugs from internal sites of the peptide  
a. Hypothesis                 
The prodrugs that we have synthesized spontaneously convert under physiological 
conditions (pH = 7.2 and temperature=37˚C) to yield the parent drug. As explained in the 
hypothesis, the pH and temperature were relied upon for this conversion, as they are 
virtually invariant physiologically and this also eliminates the need for any specific 
enzyme mediated processing of the prodrug to its active form. The prodrug chemistry that 
has been established at the N-terminal end of GLP should also be translatable for use at 
other bio-active sites from which an ester prodrug can be prepared. 
To make an ester prodrug, a judicious choice of serine/ threonine residue was 
explored at which the dipeptide could be added. The peptide must be biologically active 
before the addition of the dipeptide and inactive after the addition, in analogous fashion 
to our results at the terminal end of GLP-1. Hence, the peptide variants were tested for 
biological activity prior to pursuit of the prodrug modified forms. 
 
b. Synthesis and analysis of prodrugs at internal sites 
Two peptides were synthesized as possible starting points for development of 
internal prodrug candidates. The first peptide was (H7F),(E9Q),GLP(8-36)-CEX (Figure 
26A) and the second one was (H7F),(E9Q),(T11S),GLP(8-36)-CEX (Figure 26B).  
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Figure 26A: (H7F),(E9Q),GLP(8-36)-CEX 
 
 
 
 
 
 
*- The ester prodrug was synthesized at the circled hydroxyl group for both peptides. 
 
Figure 26B: (H7F),(E9Q),(T11S),GLP(8-36)-CEX 
 
The synthesis of an ester prodrug was attempted at the hydroxyl group of the 5th 
amino acid (threonine or serine side chain marked in Figure 26A and 26B respectively). 
For these molecules, a Boc benzyl-type synthesis on a PAM resin was conducted until the 
point of Phe at the 12th position. The rest of the synthesis was completed using Fmoc-
based chemistry. This offered the opportunity to selectively remove the protecting group 
of the serine side chain, leaving all the other protecting groups intact. This allowed for 
the selective acylation on the free hydroxyl group of the serine at the 11th position. 
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More specifically a Boc-benzyl strategy could not be used throughout the 
synthesis as the hydroxyl protecting benzyl group of serine would require HF treatment 
for removal. Consequently, an ester prodrug could not be synthesized on the peptidic 
resin as the HF treatment would simultaneous remove the peptide from the resin. This is 
why, we added the Ser at the 11th position (Fmoc-O-t butyl-L-seine) and the subsequent 
Gly, Gln, Ala and Phe as Fmoc-protected amino acids. The t-butyl protecting group of 
the serine was selectively removed by treatment with TFA for 2 hours. The Boc-protected 
dipeptidic pro-moiety was added to this hydroxyl group to finish the synthesis of the ester 
prodrug. The final Boc-protecting group was removed by treatment with TFA and the N-
terminal Fmoc group was removed by treatment with 20% piperidine in DMF. This was 
found to be a useful strategy to build the dipeptide esters from the hydroxyl side chain of 
serine and threonine residues. The glutamic acid residue at the 3rd position was also 
replaced with glutamine to prevent any unwanted coupling on the side chain carboxyl 
group. It was assumed that this would not lead to a loss of activity as previous reports 
have suggested that the 3rd position is not critical for GLP potency35. 
  The luciferase bio-assay was conducted after purification of these peptides by 
HPLC, and confirmation of their masses by MALDI as described previously. Percent 
potency was calculated and the mean EC50 of the peptide (drug candidate) was compared 
with that of native GLP-1. The results are tabulated in Table-10 and then shown in Figure 
27. 
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Serial No 
/ (Color) 
Peptide (t1/2) EC50 ± Std. 
deviation (nM) 
% potency with 
respect to GLP-1 
1 (black) GLP-1 0.02 ± 0.00 100%  
2 (pink) F7Q9S11-GLP8-36 CEX 0.10 ± 0.02 20 % 
3 (gold) F7Q9T11-GLP8-36 CEX 0.06 ± 0.02 33.33 % 
GLP-1 was used as a standard. The color codes refer to the colors with which the respective peptides are 
represented in Figure25. 
 
Table 10: Bioassay results of internal serine/ threonine drug candidates 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Bioassay of internal serine/ threonine ester prodrugs 
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The peptides (H7F),(E9Q),GLP(8-36)-CEX and (H7F),(E9Q),(T11S),GLP(8-36)-
CEX were full agonists with 20% and 33.3% the potency of native GLP-1 respectively. It 
was decided that both these peptides were sufficiently potent for development as potential 
drug candidates.  
The lower potencies of these GLP-CEX analogs as compared to GLP probably 
results from the H7F modification (as had been previously shown in this report). In this 
context, we assume that the E9Q modification does not lower the potency substantially 
(personal communication with John Day). However, previously reported structure-
activity relationship data of GLP has been based on single substitution of the 
corresponding amino acid by alanine35. In our case, both the H7F and E9Q modifications 
have been changed simultaneously in the same peptide and this might yield an 
unexpected result. 
A Gly-Gly dipeptide was envisioned to be added to these GLP analogs to study 
the type of reaction as depicted in Figure 28. This dipeptidic pro-moiety was chosen as an 
initial case on the basis of its synthetic ease; not it’s extended half life. The hydroxyl 
group of the serine side chain was easier to acylate as compared to the bulkier threonine 
side chain. One potential prodrug (H7F),(E9Q),[T11S-Oβ-(Gly-Gly)],GLP(8-36)-CEX 
was synthesized by adding a Gly-Gly dipeptide to the hydroxyl of the serine side chain as 
shown in Figure 26. In this regard, the t1/2 of the Gly-Gly terminal ester prodrugs were ~1 
hr (Table 7), whereas the t1/2 of the internal ester prodrug was found to be approximately 
three times longer.    
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Figure 28: Conversion of serine ester prodrug (H7F),(E9Q),[T11S-Oβ-(Gly-
Gly)],GLP(8-36)-CEX to drug (H7F),(E9Q),(T11S),GLP(8-36)-CEX 
 
Unfortunately, it was not possible to acylate the hydroxyl of the threonine side 
chain with a Gly-Gly dipeptide. This analogous addition of the dipeptide to Thr relative 
to Ser failed probably because of the steric restraints imposed by the methyl group at C-3 
of the threonine side chain as compared to the hydrogen at C-3 of the serine side chain. 
It was observed that the (H7F),(E9Q),[T11S-Oβ-(Gly-Gly)],GLP(8-36)-CEX 
prodrug dissociated with a t1/2 = 2.7 hrs to yield the parent drug 
t1/2 = 3 hrs 
+ 
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(H7F),(E9Q),(T11S),GLP(8-36)-CEX along with the 2,5-diketopiperazine (DKP). We 
were unable to determine the absolute potency of this prodrug because its half life is 
lower than the incubation period of the prodrug in the cell culture based luciferase assay 
(5 hrs). The half life
 
of the prodrug (2.7 hrs) indicates that approximately 70% of the 
prodrug would have converted to the active entity in 5 hours; hence the assay could not 
be accurately performed on this prodrug. However, we have nevertheless established the 
conversion of the internal serine prodrug to the active entity. 
Since the conditions for the conversion of the prodrugs to the drug (pH = 7.2 and 
temperature=37˚C) are virtually invariant physiologically, it was found that the prodrug 
chemistry that was established at the O-terminal end of GLP could be used to cleave from 
an internal site as well, specifically Ser but conceptually Thr. Thus our initial hypothesis 
is validated. 
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E) Conclusion:  
   Clinical studies have revealed that GLP-1 therapy is an effective treatment for 
Type II diabetes. In addition, it might be intrinsically safer than insulin therapy because 
of its glucose dependent action, thus eliminating the chances of hypoglycemia49. So far 
no cases of hypoglycemia have been reported using treatment with a GLP-related drug. 
An ideal prodrug should be stable to storage but must convert to the active drug 
under a specific set of conditions. The desired set of conditions for the activation of the 
prodrug will depend on its purpose and site of action. Detailed stability studies are 
important for the rigorous characterization of promising prodrugs. However, a rapid 
screening helps in the identification of such prodrug candidates.  Such screening provides 
insights to the structure, stereochemistry and the site of attachment of the pro-moiety to 
the drug and how these affect the conversion of the inactive prodrug to the active drug. In 
the work presented here, the conditions for the conversion are a pH of 7.2 and 
temperature of 37°C. These conditions were used for the cleavage of the prodrugs as they 
are physiologically invariant and can thus be translated into other peptidic drugs as well. 
The relative potency of prodrug candidates to the parent drug were determined through a 
receptor-based cell culture assay. 
Prodrug strategies have often been implemented to improve the efficacy and 
safety of important drugs in different diseases79. In this report, the prodrug strategy has 
been used to increase the time action of the GLP analog by extending the half life of the 
prodrug. Although a number of different pro-moieties could be used, the ‘dipeptide pro-
moiety or the α hydroxyl dipeptide analog’ which dissociated by the formation of 
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diketopiperazine (DKP) or diketomorpholine (DMP) along with the release of the active 
GLP analog over a wide time range was chosen. 
Our strategy has a number of advantages. Firstly, a number of structurally diverse 
amino acids (aliphatic, aromatic, acidic, basic, neutral) and α hydroxyl amino acids are 
commercially available. Secondly, given the natural nature of amino acids there is likely 
to be fewer safety and immunogenic concerns regarding their use as pro-moieties. In this 
context, it should also be noted that the native amino acid sequence was maintained as far 
as possible, and this should minimize potential adverse immunogenic responses. 
However the magnitude and nature of such adverse reactions will need to be explored in 
vivo. Thirdly, the amino acid properties and peptide synthetic chemistries are well 
established. Finally, and most importantly the chemistry of diketopiperazine formation 
allowed at least four points where the structure could be stereochemically controlled to 
refine the formation rate of the active GLP analog. Prodrugs of varying half lives were 
synthesized by chemically modifying R1 and R2 in the context of different nucleophiles 
(Figure 6). This generated the novel chemoreversible prodrugs of GLP, which converted 
to the active entity via the intramolecular cyclization and subsequent release of 2,5-
diketopiperazine (DKP) or 2,5-diketomorpholine (DMP). The large variance of half lives 
amongst the various prodrugs ranging from a t1/2 = 0.5 - 64.0 hrs underscores the great 
potential of this chemoreversible prodrug system in accurately tailoring the release of the 
parent drug under physiological conditions. The prodrug F5V6-O-F7,GLP(8-36)-CEX 
with a t1/2 = 64 hrs is the longest acting chemically defined peptidic prodrug reported to 
date. 
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Four different varieties of prodrugs (Class 1, 2, 3 and 4) of GLP or biologically 
active GLP analogs were synthesized. Both the amide and the ester prodrugs were 
synthesized in good yield. In the beginning, the amide prodrugs were synthesized by 
adding a dipeptide to the amine group at the N-terminus. The cleavage of the amide bond 
of interest was attempted under physiological conditions with both an amine and a 
hydroxyl nucleophile (Table 4 and 5). Different leaving groups were employed, with a 
histidine (Table 2), phenylalanine (Table 3 and 4) and a glycine (Table 5) at the N-
terminus of GLP analogs. For solubility purposes, we decided to work with a C-terminal 
modified GLP analog, GLP-CEX.  
We observed that the amide bond could not be dissociated by 2,5-
diketopiperazine (DKP) or 2,5-diketomorpholine (DMP) formation under physiological 
conditions. In fact, the amide bond could not be cleaved even when heated at 100°C at a 
pH=7.2. Consequently, an amide prodrug could not be synthesized using this approach. 
As a result, our attention focused on synthesizing ester prodrugs.  
Two distinct classes of dipeptide esters were tested to study the cleavage of the 
ester bond.  Class 3 variants employed an N-terminal amine nucleophile while Class 4 
variants contained a hydroxyl nucleophile to cleave the ester bond (see Figure 10).  
Selectively acylating the α-hydroxyl group of HO-H7,GLP(8-36)-CEX proved to be very 
difficult in the absence of a “protected” imidazole peptide. Hence, we decided to work 
with phenyllactic acid and subsequently synthesized the HO-F7,GLP(8-36)-CEX which 
was found to be at least as potent as the native GLP in repetitive analysis. The ester 
prodrugs were synthesized using this parent drug as the scaffold. 
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The esters proved to be much more labile than the corresponding amides and most 
of the ester prodrugs dissociated to give the active drug under physiological conditions 
along with the assumed formation of 2,5-diketopiperazine (DKP) or 2,5-
diketomorpholine (DMP). The degradation half lives of the respective prodrugs were 
calculated based on the first order kinetics (t1/2 = .693/k) where ‘k’ is the first order rate 
constant for the degradation of the prodrug. The disappearance of the prodrug and the 
appearance of the drug were both simultaneously analyzed and calculated using HPLC. 
Generally, there was an excellent mass balance between the loss of the prodrug and the 
appearance of the drug. However in our results, only the estimated half life of the 
disappearance of the prodrug has been reported. 
A sample kinetic profile reflecting the disappearance of the prodrug 
(H7F),(E9Q),[T11S-Oβ-(Gly-Gly)],GLP(8-36)-CEX and the appearance of the parent 
drug (H7F),(E9Q),(T11S),GLP(8-36)-CEX (Figure 28) under physiological conditions is 
shown in Figure 29. The slope of the first order plot (blue diamonds) represents the 
dissociation constant of the prodrug from which the half life was calculated to be 2.8 hrs. 
The experiment was performed over several half lives and the recovery of the parent 
compound was more than 90%. 
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 Blue diamonds represent the disappearance of the prodrug. 
 Pink squares represent the appearance of the drug. 
The logarithm of the concentrations of the prodrug (blue) and the drug (pink) were plotted on the y 
axis as a function of time on the x axis.  
 
Figure 29: Typical kinetic profile showing the disappearance of a prodrug and the 
appearance of a drug 
    
Of all the ester prodrugs that were studied, only two did not cleave and they are 
represented in Figure 30. 
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1: HO-F5V6-O-F7,GLP(8-36)-CEX          2. HO-G5tBut6-O-F7,GLP(8-36)CEX 
 
Figure 30: Ester prodrugs resistant to cleavage 
 
 The most likely reason for this is the increased size of the R1 and R2 in 
compounds 1 and 2 (Figure 30). The steric bulk of the isopropyl and tertiary butyl group 
crowds the transition state increasing the activation barrier for the intramolecular 
cyclization. As a result, the cyclization does not occur. When the hydroxyl nucleophile in 
compound 1 was replaced with the amine, the corresponding F5V6-O-F7,GLP(8-36)-CEX 
(Figure 18B) cleaved with a long half life of 64.0 hours. The presence of cleavage 
relative to the hydroxyl-peptide is because the amine is a stronger nucleophile, as 
compared to the hydroxyl. Thus it is seen that the chemical stability of the ester bond is 
influenced by the structure of the amino acid promoieties. The bulk of the side chain of 
the corresponding amino acids and the strength of the nucleophile play a role in the 
cleavage of the ester prodrugs. Additionally, stereochemistry of the two amino acids 
further influences the rate of cleavage.  These results are consistent with related 
observations in the field of DKP-like prodrugs61,63. 
 Our primary goal was to synthesize longer-acting prodrug candidates of GLP with 
a daily or even a weekly dosage. This is especially important as the longest acting DPP-
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IV resistant GLP analog (Liraglutide) that is presently in Phase III trials has a biological 
half life of 10-14 hrs47,48. Four prodrug candidates with varying half lives of 20.3hrs, 
33.3hrs, 50.5 hrs and 64.0 hrs were successfully synthesized (Figure 23 and Appendix I). 
Each of these prodrug candidates should display extended duration of in vivo action and 
possibly constitute ‘once a week’ formulations, since this prolongation would be in 
addition to the natural time action of the parent drug. 
The bio-assay we used is highly sensitive and reproducible. All the prodrugs have 
minimal inherent receptor potency relative to the parent drug (Table 8). The potency of 
G5V6-O-F7,GLP(8-36)-CEX is nearly restored quantitatively (Figure 31A), while that of 
HO-F5F6-O-F7,GLP(8-36)-CEX is only  partial after incubation in PBS at 37˚C for 24 
hours (Figure 31B). The reason for latter observation is not immediately clear; and 
warrants further study.  
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Green: GLP-1; Black: HO-F7,GLP(8-36)-CEX 
 Red: G5V6-O-F7,GLP(8-36)CEX after incubation in PBS for 1 week; 
Yellow: G5V6-O-F7,GLP(8-36)CEX after incubation in PBS for 24 hours;  
 Pink: G5V6-O-F7,GLP(8-36)CEX in PBS at 0 hours; 
 
Figure 31A: Relative potency of G5V6-O-F7,GLP(8-36)CEX 
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 Light blue: HO-F5F6-O-F7,GLP(8-36)-CEX after incubation in PBS for 24 hours; 
 Dark blue: HO-F5F6-O-F7,GLP(8-36)-CEX in PBS at 0 hours; 
 
Figure 31B: Relative potency of HO-F5F6-O-F7,GLP(8-36)-CEX 
 
The biological potency of the internal serine ester prodrug, (H7F),(E9Q),[T11S-
Oβ-(Gly-Gly)],GLP(8-36)-CEX could not be determined as its half life (2.8 hrs) is much 
shorter than the incubation period (5hrs) in the luciferase assay. However, its chemical 
conversion to the active (H7F),(E9Q),(T11S),GLP(8-36)-CEX (Figure 28 and 29) has 
been documented validating that the diketopiperazine chemistry is feasible from an 
internal ester site of the peptide. The internal ester prodrug (H7F),(E9Q),[T11S-Oβ-(Gly-
Gly)],GLP(8-36)-CEX cleaves with a half life that is longer than the terminal prodrug 
G5G6-O-F7,GLP(8-36)-CEX. The reason for this might be that the β-ester bond of the 
internal prodrug is more resistant to cleavage than the terminal α-ester bond. 
In the overall context of things, we would have much preferred to have been able 
to cleave both the amide and ester bonds. This would provide the opportunity to utilize 
this prodrug chemistry at amine as well as hydroxyl containing drug candidates. One 
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central disadvantage of ester prodrugs is the ubiquitous presence of esterases in vivo; and 
hence the effective half life of the ester prodrug might be much faster in blood then 
reported here.   
In conclusion, our prodrugs were extremely stable when stored as a powder at 
4°C. They are soluble in physiological buffers, and exhibit differential conversion rates to 
the active drug under physiological conditions. This latter point is the central importance 
of my work. The results of this study clearly indicate that the cis-conformation of the 
dipeptide favors cleavage. Furthermore, that the overall structure (especially β branching 
as evidenced by the slow rates in pro-moieties containing valine), stereochemistry of the 
side chains, and the strength of the nucleophile play a profound role in affecting the rates 
of prodrug cleavage. It was also importantly shown that rate of conversion can be fine-
tuned by selecting the structure of the pro-moieties. This is of utmost importance in the 
design of a properly functioning prodrug, as represented in Figure 32. The dynamic range 
in rate of cleavage ranged from an hour to almost half a week. This provides appreciable 
opportunity for choosing from a wide spectrum of potential prodrugs, each varying in 
duration of action. These prodrugs with their tailored rate of conversions can provide a 
versatile lead for further optimization of their pharmacological profiles.  
 
  88 
0
10
20
30
40
50
60
70
Half life (hrs)
OH-
Gly -
PhG 
OH-
Gly-
Phe 
OH-
Gly -
AIB 
Gly-
Gly
OH-
Gly-
dPhe 
OH-
Gly-
Gly 
OH-
Phe-
dAla 
OH-
Phe-
Gly 
OH-
Phe-
Ala 
OH-
Gly-
Val 
OH-
Gly-
dVal 
OH-
Phe-
dPhe
Gly -
Val 
OH-
Phe-
Phe
OH-
Phe-
dVal 
Phe-
Val 
OH-
Gly -
tBut 
OH-
Phe-
Val 
Prodrugs
Varied half lives of different prodrugs
  
 
Yellow: Prodrugs with t1/2 under 5 hrs; Green: Prodrugs with t1/2 under 10 hrs  
Blue: Prodrugs with t1/2 between 20 to 65 hrs; Red: Prodrugs that did not dissociate at all  
 
Figure 32: Prodrugs with varying half lives 
  
 It is envisioned that the half lives of these prodrugs might be different when 
studied in vivo than reported in our in vitro experiments. This will probably be as a result 
of the action of the esterases and other enzymes, but unlikely a change in the chemical 
rate of conversion. Hence, an in vivo characterization of these prodrugs shall be 
necessary. Even if the prodrugs display the required half life in vivo, it might be required 
to slow their renal clearance (the renal threshold is 38,000 Da while the prodrugs have a 
molecular weight of ~4500). This can be done by pegylating the prodrugs at appropriate 
residues. 
 A place for additional investigation is the identification of methods to cleave 
amide prodrugs under physiological conditions. The amide prodrugs will presumably 
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have an enhanced half life relative to that of the ester prodrugs. However, the increased 
flexibility of using amine-based drugs and their prodrugs to escape what might be 
selective degradation by esterases warrants further investigation.  
 We have observed a number of prodrugs that could be potentially administered on 
a ‘once a week’ basis. Even longer acting prodrug candidates might be desired. Those 
will be prodrugs that can be administered on a ‘once a month’, or even in a ‘once a year’ 
formulation. However, it is worth noting that there are many other mechanisms beyond 
‘diketopiperazine formation’ by which the prodrugs can be destroyed in vivo. Since 
peptides intrinsically decompose in vivo under physiological conditions, there is a limit 
set to the “time of action” of a specific peptide-based drug. However, our ability to use 
inverted stereochemistry of the dipeptide with no change in rate of chemical cleavage is a 
huge advantage in minimizing enzymatic destruction of the prodrug element.  
The studies of the structure of additional pro-moieties and how they affect the rate 
of conversion will provide additional diversity in prodrug chemistry for future use. This 
might then lead to a more effective structure-activity correlation study which can be 
subsequently used to synthesize prodrugs of optimal stability and pharmacokinetic 
profiles. 
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Appendix I: Schematic synthesis of longer-acting prodrugs 
A) Synthesis of HO-F5dV6-O-F7,GLP(8-36)-CEX 
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B)  Synthesis of F5V6-O-F7,GLP(8-36)CEX 
 
H
OH OH H2N
CH2Ph
OH
H
H
N
O
+
0.9 mmol DEPBTinDMF
+0.5 ml DIEA
(6hrs at roomtemp)
O
CH2Ph
GLP(8-36) CEX
H
O
BocNH OH
1) 1.0mmol DICinDCM(0oC)
+0.9 mmol DMAP
(12hrs at roomtemp)/
2) TFA
O
NH2
H
O H
CH2Ph
H O
CH2Ph
BocNH OH
1)1.9mmol DEPBTin DMF
+ 1ml DIEA/
2) TFA
O
NH
H
O
O
H CH2Ph
NH2
H
CH2Ph
O
H2
C PAM
GLP (8-36)CEX O
H2
C PAM
O
NH
H
O
O
H CH2Ph
NH2
H
CH2Ph
GLP(8-36)CEX
GLP (8-36)CEX O
H2
C PAM
GLP (8-36)CEX O
H2
C PAM
HF(1hr)
(0.2mmol)
6
5
(1 .0mmol)
(2 .0mmol)
(2 .0mmol)
 
 
 
 
 
  97 
C) Synthesis of HO-F5F6-O-F7,GLP(8-36)-CEX 
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D) Synthesis of G5V6-O-F7,GLP(8-36)CEX 
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Appendix II: Structure of peptides in Table 2 
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Appendix III: Structure of peptides in Table 3 
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Appendix IV: Structure of peptides in Table 4 
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Appendix V: Structure of peptides in Table 5 
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Appendix VI: Structure of peptides in Table 6 
 
Serial No Structure 
1.  
O
NH
H
O
O
H
NH2
H
CH2Ph
H
GLP(8-36) CEX
H
 
2.  
O
NH
H
O
O
H H
OH
H
CH2Ph
H
GLP(8-36) CEX
 
3.  
O
NH
H
O
O
H CH2Ph
OH
H
CH2Ph
GLP (8-36)CEX
 
 
 
  106 
Serial No Structure 
4.  
O
NH
O
O
H CH2Ph
OH
H
CH2Ph
H
GLP(8-36) CEX
 
 
5.  
O
NH
H
O
O
H CH2Ph
OH
H
CH2Ph
CH3
GLP(8-36) CEX
 
 
6.  
O
NH
O
O
H CH2Ph
OH
H
CH2Ph
H
H3C
GLP(8-36) CEX
 
 
  107 
Serial No Structure 
7.  
O
NH
H
O
O
H CH2Ph
OH
H
CH2Ph
H
GLP(8-36) CEX
 
 
8.  
O
NH
H
O
O
H CH2Ph
OH
H
CH2Ph
CH2Ph
GLP(8-36)CEX
 
 
9.  
O
NH
O
O
H CH2Ph
OH
H
CH2Ph
H
CH2Ph
GLP(8-36) CEX
 
 
 
  108 
Serial No Structure 
10.  
O
NH
H
O
O
H CH2Ph
NH2
H
CH2Ph
GLP (8-36)CEX
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  109 
Appendix VII: Structure of peptides in Table 7 
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Appendix VIII: Acylation of HO-His7,GLP(8-37) 
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Appendix IX: Synthesis of (H7F),(E9Q),(T11S),GLP(8-36)-
CEX 
FTSDVSSYLEGQAAKEFIAWLVKGR-CEX O
H2
C PAM
H2N FTSDVSSYLEGQAAKEFIAWLVKGR-CEX
H
O
H2
C PAM
H2N
H O
CH2O-t-butyl
FmocNH OH
i) 1.9mmol DEPBTin DMF
+ 1ml DIEA/
ii) 20%piperidine inDMF
O
1)
2) 2 .0mmol Fmoc-Gly i)1.9mmol DEPBTinDMF
+ 1ml DIEA/
ii) 20%piperidine inDMF
3) 2 .0mmol Fmoc-Gln i)1.9mmol DEPBTinDMF
+ 1ml DIEA/
ii) 20%piperidine inDMF
4) 2 .0mmol Fmoc-Ala i) 1.9mmol DEPBTinDMF
+ 1ml DIEA/
ii) 20%piperidine inDMF
5) 2 .0mmol Fmoc-Phe i)1.9mmol DEPBTinDMF
+ 1ml DIEA/
(0.2mmol)
H
H
t-butyl-O
O
H2
C PAM
butyl-t-O
H
N
FTSDVSSYLEGQAAKEFIAWLVKGR-CEX
HFAQG
O
H
H
FmocHN
(2 .0mmol)
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HO
H
N
FTSDVSSYLEGQAAKEFIAWLVKGR-CEX
HFAQG
O
H
H
1) TFAfor 2hrs
2) 20%piperidine
O
H2
C PAM
HFcleavage
H
N
FTSDVSSYLEGQAAKEFIAWLVKGR-CEX
HF7AQ9G
HO H
H
O
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Appendix X: Synthesis of (H7F),(E9Q),[T11S-Oβ-(Gly-
Gly)],GLP(8-36)-CEX 
 
1)2 .0mmol tBoc-Gly i)1.0 mmol DICinDMF9(0oC)
+ 0.9 mmol DMAP
(12 hrsat roomtemp)
ii) TFA
2) 2 .0mmol tBoc-Gly i) 1.9 mmol DEPBTinDMF
+ 1ml DIEA/
ii) TFA
O
H2
C PAM
butyl-t-O
H
N
FTSDVSSYLEGQAAKEFIAWLVKGR-CEX
HFAQG
O
H
H
FmocHN
TFA
O
H2
C PAM
HO
H
N
FTSDVSSYLEGQAAKEFIAWLVKGR-CEX
HFAQG
O
H
H
FmocHN
H
N
FTSDVSSYLEGQAAKEFIAWLVKGR-CEX
HFAQG
OO
N
NH2O
H
H
H
H
H
H
O
FmocHN
O
H2
C PAM
(0.2mmol)
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20% piperidine
H
N
FTSDVSSYLEGQAAKEFIAWLVKGR-CEX
HFAQG
OO
N
NH2O
H
H
H
H
H
H
O
H2N O
H2
C PAM
HF cleavage
H
N
FTSDVSSYLEGQAAKEFIAWLVKGR-CEX
HF7AQ9G
OO
N
NH2O
H
H
H
H
H
H
O
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Appendix XI: A note on nomenclature 
A. Native GLP-1(7-37)-acid has been listed as GLP throughout this thesis. Its 
sequence is: 
HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-acid 
 
B. F7,GLP(8-37) refers to the GLP analog where the His at the 7th position has been 
replaced by Phe. The analog is: 
      FAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-acid 
 
C. The GLP(7-36)-CEX amide has been designated as GLP(7-36)-CEX throughout 
this thesis. The CEX sequence (in red) is the C-terminal nine amino acids of 
exendin-4 where the C terminus is a serine amide. Its sequence is: 
H7AEGTFTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS-amide  
Changes have been made to the nomenclature to signify analogous peptides. For 
example, the sequence of HO-F7,GLP(8-36)-CEX is: 
    HO-F7AEGTFTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS-amide 
 
D. The amide prodrugs designated as X5Y6H7,GLP(8-37) and X5Y6F7,GLP(8-37) 
refers to the prodrugs synthesized on the native GLP and F7,GLP(8-37) 
respectively. The sequence of X5Y6H7,GLP(8-37) is shown below: 
      X5Y6H7AEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-acid 
The structure of such amide prodrugs (amine and hydroxyl nucleophile) is 
represented below: 
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O
NH
O
NH2/OH
HN H7AEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-acid
H
R6
H
R5
6
5
 
 
E. The ester prodrugs are designated as X5Y6-O-F7,GLP(8-36)-CEX with an amine 
nucleophile:  
      X5Y6F7AEGTFTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS-amide 
and HO-X5Y6-O-F7,GLP(8-36)-CEX with a hydroxyl nucleophile respectively.  
HO-X5Y6-O-F7AEGTFTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS-amide 
The structure of such ester prodrugs (amine and hydroxyl nucleophile) is 
represented below: 
 
6
5
O
NH
O
NH2/OH
O F7AEGTFTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS-amide
H
R6
H
R5
 
          
F. The preliminary peptides for the synthesis of the internal ester prodrugs are 
(H7F),(E9Q),GLP(8-36)-CEX and (H7F),(E9Q),(T11S),GLP(8-36)-CEX. The 
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mutations from the native sequence are represented in parenthesis and shown in 
red. The sequence of (H7F),(E9Q),GLP(8-36)-CEX is : 
F7AQ9GTFTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS-amide 
and the sequence of (H7F),(E9Q),(T11S),GLP(8-36)-CEX is:  
F7AQ9GS11FTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS-amide 
 The structure of (H7F),(E9Q),(T11S),GLP(8-36)-CEX is given by: 
 
OH
N
FTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS-amide
HF7AQ9G
HO H
H
 
 
G.  The internal ester prodrug designated as (H7F),(E9Q),[T11S-Oβ-(Gly-
Gly)],GLP(8-36)-CEX was synthesized from the serine at the 11th position of 
(H7F),(E9Q),(T11S),GLP(8-36)-CEX. The (Gly-Gly) dipeptide pro-moiety 
(shown in red) was added to the S11. The sequence of (H7F),(E9Q),[T11S-Oβ-
(Gly-Gly)],GLP(8-36)-CEX is given by: 
F7AQ9GS11FTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS-amide 
                          GG 
  The structure of (H7F),(E9Q),[T11S-Oβ-(Gly-Gly)],GLP(8-36)-CEX is  
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OH
N
FTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS-amide
HF7AQ9G
OO
N
NH2O
H
H
H
H
H
H
 
 
 
 
 
 
 
 
 
 
